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PROVIDER RECOMMENDATIONS FOR HUMAN PAPILLOMAVIRUS
VACCINE (HPV) AMONG ADOLESCENT MALES IN SOUTHWEST GEORGIA
COUNTIES AND THE ASSOCIATED HPV PREVALENCE IN THIS POPULATION

by
BENJAMIN POKU
(Under the Direction of GULZAR SHAH)
ABSTRACT
Objective: The purpose of this research study was to examine the variation in
healthcare providers’ behavior in recommending the Human Papillomavirus (HPV)
vaccine to young male adolescents (aged 11-12), middle male adolescents (aged 13-17)
and late male adolescents (aged 18-26) in rural Southwest Georgia counties. This
research also aimed to identify factors associated with providers’ behaviors concerning
HPV vaccination recommendation to youth in various age groups.
Methods: Upon IRB approval, secondary data were obtained from Albany Area
Primary Care for a paper-based survey that was conducted in 2014 using a representative
random sample of family physicians (n=12), pediatricians (n=6), and nurse practitioners
(n=33). The survey had a response rate of 76% and the researcher employed descriptive
statistics, paired t tests and analysis of variance (ANOVA) to describe the pediatricians’
(Peds), nurse practitioners’ (NPs/Nurses), and family physicians’ (FPs) recommendations
to HPV vaccinations and the association of HPV prevalence in Rural Southwest GA.
Results: Statistical testing and analysis show barriers such as healthcare
providers’ and parents’ discomfort with the vaccination of pre-teens when it concerns a
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sexually transmitted disease, lack of awareness to the role that males play in the spread of
HPV, absence of government mandates, and non-completion of the three-dose series of
vaccination due to financial or logistical reasons. Provider specialty, age, ethnicity, and
reported barriers were significantly associated with recommendations and association to
HPV prevalence.
Conclusions: Findings suggest missed HPV vaccination opportunities for
adolescent males. Perceived barriers and support to HPV vaccination to providers may
drive decisions about HPV vaccine uptake and completion of vaccination series. Findings
also suggest the need for policy level interventions to increase HPV vaccination among
US adolescent males.

INDEX WORDS: HPV, Adolescent males, Health Care Providers, Vaccination,
Quadrivalent, Cervarix
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CHAPTER 1
INTRODUCTION
Statement of the Problem
Human papillomavirus (HPV) is a sexually transmitted infection (STI) that is very
common in the United States and that has been recognized as one of the most dangerous viruses
as it is linked to various genital-related health problems in males (CDC, 2013). It is responsible
for approximately 4,000 deaths annually within the country, and it is causally linked to cancers
in areas such as the anus, genitals, and oropharynx (Schiffman et al., 2011). Each year, 9,000
males in the United States contract HPV-related cancer (Dunne et al., 2014). In 2008, the vaccine
targeting HPV, Gardasil™, entered the market and was targeted at males aged between 9 and 26
years. The Centers for Disease Control Advisory Committee on Immunization Practices (ACIP)
subsequently recommended vaccination of males between 9 and 26 years of age (CDC, 2013). In
2009, another vaccine, Cervarix, was introduced into the market (CDC, 2010). Despite a wave
of federal and state policy initiatives aimed at promoting the vaccine’s use, a review of pertinent
literature shows that there exist several barriers to the vaccination efforts. Research indicates that
primary healthcare providers’ recommendations are a key factor for vaccine uptake among
adolescents (Vadaparambil et al., 2011). The purpose of this paper is to describe healthcare
providers’ recommendations to HPV vaccine to adolescent males.
Current Situation
The HPV virus is responsible for over 70% of cervical cancer cases. The HPV virus
vaccination is currently recommended for girls 9 to 12 years of age and can also be administered
for ages 13 to 26 (CDC, 2012). It is more effective if given before the girls’ first sexual contact.
Absent vaccination, the only recommended and sure way of preventing infection with the HPV
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virus is by total abstinence from sexual intercourse since the virus can be transmitted by the areas
not covered by a condom even if a condom is used. As such, concerted efforts ought to be
employed to avoid infection by vaccinating men as well as women (Shi, 2008). Currently the
emphasis on HPV vaccination is skewed towards females, but this research proposes a balanced
approach by targeting adolescent males for HPV vaccination as well.
The many opposing opinions about HPV vaccinations can affect funding and research
efforts concerning the effects of HPV among males (Siu, 2014). Recommendations by the Joint
Committee on Vaccination and Immunization (JCVI) to introduce vaccination in boys have
attracted criticism. The implementation of these JCVI recommendations would show that the
male adolescent benefits from the vaccination. Boys would have minimal chances of contracting
and spreading the HPV and HPV-related cancers. Among sexually transmitted diseases, HPVrelated infections are the most common in the US. In fact, it is estimated that 14 million US
citizens are infected with this virus annually. The number of people suffering from the disease at
any given time is about 70 million. Of the 150 identified strains of the HPV, 40 are carcinogenic
and believed responsible for causing different types of cancers such as cervical cancer, as well as
some less common types of cancers such as cancers of the anus and vagina (Stocker, Dehnert,
Schuster, Wichman, & Delere, 2013).
Two types of vaccines against HPV infections are currently available. These include
bivalent (Cervarix) and quadrivalent (Guardasil) vaccines. These vaccines are totally effective
against strains 16 and 18 which are the most potent causative agents of cervical cancer. Usually
three shots of the vaccine are given to protect against HPV. These shots are administered as a
series over a period of six months. Immunity against cervical cancer in women is provided using
Cervarix and Gardasil. Gardasil is also effective in preventing genital warts, and vaginal, anal,
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and penile cancers. Cervarix, however, is effective only against the strains of HPV that cause
cervical cancers. The vaccines are effective when given to preteen boys and girls before they
become sexually active. As such, the vaccine is currently recommended for preteen boys and
girls (Vadaparampil et al., 2011).
In addition to preteen girls and boys, the HPV vaccine is also currently recommended to
teenage boys and girls who might not have been vaccinated at an earlier age. For males, the
vaccine is recommended to be given through to the age of 21, but can be administered to males
up to age 26. It is also recommended for men who engage in sex with other men, and for men
with compromised immune systems. (CDC, 2012). Girls should be vaccinated up the age of 26.
Vaccinations done after these ages have proven not to be effective (Vadaparampil et al., 2011).
Purpose Statement
This study will generate knowledge that will identify issues surrounding primary
healthcare providers’ frequency of recommending the HPV vaccine to male adolescents aged
11–26 in Southwest Georgia.
Due to the burden of morbidity, mortality, and financial cost associated with this virus,
the vaccine targeting HPV, Gardasil™, entered the market to target males aged between 9 to 26
years. This also caused ACIP to recommend male immunization and vaccination against the
virus targeting those between 9-26 years of age (CDC, 2013).
This research examined the prevalence of providers’ recommendation of HPV
vaccination to early male adolescents (aged 11-12), middle male adolescents (aged 13-17) and
late male adolescents (aged 18-26), as well as finding the factors associated with such
recommendations, mainly in early male adolescents. The rationale for grouping of early, middle,
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and late adolescents is due to the hormonal and physical differences that can be seen among
these age groups. The CDC also recommends vaccination to start at 11-12 years of age.
Concept of the Study
The purpose of this study is to identify the effects of missed vaccination opportunities to
a community’s health. Specifically, this researcher will seek to identify the relationship between
the rate at which health care providers recommend HPV vaccine and the prevalence of HPVrelated diseases. In this, the effects of missed HPV vaccination opportunities will be revealed. It
is expected that low rates of HPV vaccine recommendation will translate to high prevalence rates
of HPV-related diseases among the population. The study will also look at the support and
barriers healthcare providers encounter to recommending HPV vaccine (Gostin & DeAngelis,
2007).
The study will encompass at several factors that affect the rate at which healthcare
providers recommend the HPV vaccine to their patients, and as well as factors that contribute to
missed vaccination opportunities including how attitudes, culture, and financial factors affect
healthcare providers’ recommending or not recommending the vaccine. Therefore, this study will
help identify solutions that will prevent the spread HPV-related infections (Gamble, Klosky,
Parra, & Randolph, 2010).
Terms and Definitions
Health Care

General community efforts to diagnose disease, treat disease, and prevent
disease from developing. It requires the input of both individuals and the
community such as practitioners in allied health. A healthcare venue
allows the provision and accessibility to resources and conditions that
foster individual health-promoting behaviors. Health care refers to the
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work done by primary, secondary, and tertiary care professionals, as well
as public health.
Primary Care

The first point of entry by a consumer of health (patient) into the
healthcare delivery system. This venue carries out public health
functions of primary prevention, such as immunizations. While primary
care providers normally treat individual patients, public health takes a
population-health approach to disease prevention and interacts with
policy makers that implement policies and programs within the
healthcare delivery and utilization system.

Health Behavior Health behavior refers to the actions of people and communities that
result in social change, policy development, and health improvement. It
aims either to prevent disease or to detect health problems.
Primary

Primary prevention is the ability to change an individual’s susceptibility

Prevention

to a health problem and also reduce the exposure to a causal agent.
Public health is the primary prevention agency that is involved in
epidemiological study in finding risk factors associated to the health of a
population in general and possibly preventing or eliminating infections.

Population–at-

Population-at-risk includes cohorts or persons who may contract a

risk

disease or develop a health problem. In this study adolescent males are
the cohort or prospective population at risk.

Quality of Care

The Institute of Medicine (IOM) defines quality of care as safe, effective,
patient-centered, timely, efficient, and equitable for individuals and
populations. This research may improve access to preventive care by
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providing a better understanding of healthcare providers’ HPV vaccine
recommendations.
Research Setting
Albany Area Primary Health Care, Inc. is an affiliate of the Georgia Association for
Primary Health Care (GAPHC) and also a Federally Qualified Health Center (FQHC). It is
located in Albany, GA, and provides healthcare services to rural and underserved communities in
Southwest GA.
Research Questions/Hypotheses
The focus of this study will be on providers’ tendency to recommend HPV vaccine to
early male adolescents (ages 11-12), as evidence indicates that this is the best age to introduce
the HPV vaccine to ensure long-term effectiveness.
Research Question A
Are healthcare providers' rates of recommending HPV vaccination for males aged 11 to
12 years old higher than those of males aged 13 to 17 years old?
Null Hypothesis
No difference exists between healthcare providers’ prevalence of recommending HPV
vaccines to either early (ages 11-12) adolescent or middle (ages 13-17) adolescent males.
Alternate Hypothesis
A difference exists between the healthcare providers’ prevalence of recommending HPV
vaccines to early (ages 11-12) adolescent and middle (ages 13-17) adolescent males.
Research Question B
Are healthcare providers' rates of recommending HPV vaccination for middle adolescent
males (ages 13-17) higher than those of late adolescent (ages 18–26 years) males?
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Null Hypothesis
No difference exists between healthcare providers’ prevalence of recommending HPV
vaccines to either middle adolescent or late adolescent males.
Alternate Hypothesis
Differences exist between healthcare providers’ prevalence of recommending HPV
vaccines to middle adolescent and late adolescent males.
Research Question C
Are healthcare providers' rates of recommending HPV vaccination for early adolescent
males (ages 11-12) higher than those of late adolescent males (ages 18-26)?
Null Hypothesis
No difference exists between healthcare providers’ prevalence of recommending HPV
vaccines to either early adolescent (ages 11 -12) or late male adolescent males (ages 18-26).
Alternate Hypothesis
Differences exist between healthcare providers’ prevalence of recommending HPV
vaccines to early adolescence (ages 11-12) and late adolescence males (ages 18-26).
Research Question D
Is there a variation in rates at which specialist healthcare providers’ (FPs, NPs, Peds)
recommend HPV vaccines?
Null Hypothesis
No difference exists between specialist healthcare providers in their prevalence of
recommending HPV vaccines to patients.
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Alternate Hypothesis
Differences exist between specialist healthcare providers in their prevalence of
recommending HPV vaccines to patients.
Research Question E
Are healthcare providers' encountering perceived barriers in recommending HPV vaccine
to adolescent males?
Null Hypothesis
No perceived barriers exist among healthcare providers’ prevalence of recommending
HPV vaccines to adolescents males
Alternate Hypothesis
Perceived barriers exist among healthcare providers’ prevalence of recommending HPV
vaccines to adolescents males
Research Question F
Is there variation in recommending rates by demographic characteristics of the provider?
Null Hypothesis
There is no variation in recommending rates by demographic characteristics of the
provider.
Alternate Hypothesis
There is variation in recommending rates by demographic characteristics of the provider.
Delimitations
This study uses secondary data obtained from a local federally qualified health center
(Albany Area Primary Care-AAPC) that operates in several counties in Southwest Georgia. The
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sample size is small and the responses may be based on regional socio-cultural and socioeconomic factors, along with other regional factors.
Significance of the Study
The quest to develop social awareness of the dangers of HPV has been assumed by
different health organizations in the United States. The lack of awareness concerning the danger
of HPV to men has led to the deaths of many unsuspecting people who succumb to various forms
of HPV-related infections (Jemal et al., 2011). The burden of HPV-related illnesses among males
is associated with primary care healthcare providers such as pediatricians (Peds), nurse
practitioners (NPs), and family physicians (FPs) missing clinical opportunities to recommend
HPV vaccination (Sudenga, Royse, & Shrestha, 2011).
Because HPV can be the causative agent for many illnesses in males such as cancers of
the anus and oropharynx, this study examines the relationship between missed vaccination
opportunities and the prevalence of the various HPV-linked illnesses. The virus is highly
transmissible directly through the skin, especially during sexual intercourse. Vaccination has
proved to be an effective method by which development of HPV-related illnesses can be
prevented. Therefore, individuals who receive the HPV vaccine are expected to have low
probability of contracting HPV-related illnesses.
The study also helps to compare the effectiveness of various HPV vaccines with that of
other methods of HPV prevention. These methods include use of condoms, abstinence, and
monogamy. According to the Youth Risk Behavior Survey (YRBS), in 2013, 46.8% of high
school teenagers were sexually active, with 15% of these reporting four or more partners (CDC,
2014). With the study revealing the various adverse consequences of missed vaccination
opportunities, adequate measures will be taken to reduce instances of missed vaccination
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opportunities. The study provides relevant information that can be used to curb HPV-linked
illnesses (Gamble et al., 2010). Mandatory HPV vaccination in Australia has greatly reduced the
prevalence of genital warts in teenagers (Ali et al., 2013). Following this logic, it is likely that
implementing HPV vaccination for adolescents in southwest Georgia would immediately begin
to reduce the incidence of adolescent genital warts here as well. However, the benefits of
reducing HPV-related penile, anal, and cervical cancers may take decades to be revealed (CDC,
2013).
Barriers that contribute to missed medical opportunities will be identified. The barriers to
be examined include health workers attitudes, cultural barriers, compliance barriers, cost
barriers, psychological barriers, and information barriers. Identification of these various barriers
serves as the starting point in solving problems arising from missed vaccinations. The study will
also identify ways through which these barriers can be overcome. Such solutions include
adoption of relevant legislation and government policies, financial support from the government,
and health workers informational drills (Goldstein, 2010). As such, the study directly suggests
the solution to missed medical opportunities by identifying support that will enhance the goal of
increasing primary healthcare providers’ rate of recommending HPV vaccination among
adolescent males.
By revealing the relationship between the likelihood of the healthcare providers to
recommend HPV vaccine and the prevalence of HPV-related diseases in a rural community of
southwest Georgia, this study can help to accomplish the public health goal of preventing poor
health outcomes among the subject population (Gostin & DeAngelis, 2007). Basically,
intervening and seeking to prevent a disease is the foundation of public primary health. In
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addition, the study will generate knowledge which when disseminated to all the stakeholders
could help bring about a healthier society (Gudeman, 2007).
This research aligns with the functions of public health that are necessary to deliver
essential health services. The study will therefore be important in monitoring the general health
status of the community. It will identify community health problems by evaluating effectiveness,
accessibility, and quality of both personal and population-based health services.
The study also reinforces the need to develop policies and plans that will support
individual and community health efforts. It will also inform, educate, and empower the
community regarding HPV-related diseases. As such the study will add to the knowledge base
regarding the HPV vaccine that is already available. This will help reduce the burden of HPVlinked diseases which includes mortality, morbidity, and high financial costs. In the US, HPVrelated diseases are the most common sexually transmitted disorders. The CDC estimates that
approximately $4 billion is expended annually to prevent and treat HPV-related diseases (CDC,
2012).
By revealing problems associated with missed vaccination opportunities, the study will
enable public health authorities to actively promote the adoption of a preventive healthcare
approach in dealing with HPV-related diseases. These efforts by public health authorities will
create awareness in the community, and the number of young men seeking the HPV vaccine will
increase. The public health authority will also encourage public health providers to administer
the HPV vaccine to all young men seeking medical attention at their health centers.
The study will be used as a road map that will set a guide for the development,
implementation, and evaluation of HPV-related health issues. In addition, the study will be used
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to understand the current behavior of healthcare providers in recommending HPV vaccines to
young patients (Hoover, Carfioli, & Moench, 2000).
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CHAPTER 2
LITERATURE REVIEW
Introduction
HPV infection is considered the most common sexually transmitted infection, with half
of the US population contracting it at some point in their lives. As it is transmitted through
sexual contact, its incidence is very high in sexually active people, especially among men who
have sex with other men. Statistically, 50% or less of heterosexual men, 61% of HIV-negative
homosexual men, and 93% of HIV-positive homosexual men have HPV infection (Brewer, Ng,
McRee, & Reiter, 2010).
Human papilloma virus (HPV) replicates in the squamous epithelial cells of the cervix,
anus, and tonsils. It can establish infection only in the keratinocytes of the skin and the mucous
layer. Most infections are asymptomatic; however, in a few cases infection can lead to warts
and/or cancers of the cervix, vagina, vulva, penis, oropharynx, and anus. Risk factors for
infection include more than one sexual partner, use of oral contraceptives, smoking, and alcohol
consumption. Use of condoms and circumcision can reduce HPV infections (Crosignani et al.,
2013).
The majority of anal and penile cancers in men worldwide are associated with HPV
infection. Gay men infected with HPV are 44 times more likely to get anal cancer. Gay men who
are both infected with HPV and HIV positive are 60 times more likely to develop anal cancer
(Newman, Logie, Doukas, & Asakura, 2013). Heterosexual men infected with HPV can increase
their sexual partner’s risk of developing cervical cancer. Hence, protection from HPV for men in
the form of vaccination becomes essential. However, for a number of reasons, vaccination is
recommended only for females and not much priority is given to vaccination for males. A
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number of school-based immunization programs have been put in place due to the alarming rates
of cervical cancer; however, all of these programs are targeted to adolescent girls. Including boys
in school-based vaccination programs is presently considered cost-ineffective and unnecessary
(Newman et al., 2013).
Preventing HPV infection can be accomplished largely through the use of two vaccines –
the quadrivalent vaccine Gardasil (Merck), and the bivalent vaccine Cervarix
(GlaxoSmithKline). The HPV risk-types that are targeted by Gardasil are HPV-16, -18, -6, and 11, whereas Cervarix targets only HPV-16 and -18.
Both of the vaccines have proven highly effective in preventing adenocarcinoma in-situ
(AIS) in women; additionally, Gardasil also prevents genital warts, vulvar and vaginal
intraepithelial neoplasia grades 1-3, and high-grade anal disease in men. However, Cervarix is
cheaper compared to Gardasil and also offers longer protection – 8.4 years, compared to 6.4
years for Gardasil. Studies have also found that Cervarix can generate higher antibody titers
compared to Gardasil. Despite all this data in favor of Cervarix, Gardasil is preferred due to its
wider range of protection (Ma et al., 2012). The safety and efficacy of both vaccines has been
very well documented, and both afford protection against 80% of all cervical cancers (Hung, Ma,
Monie, Tsen, & Wu, 2008).
Critical factors in HPV vaccination include immunogenicity, safety, and clinical
significance (Crosignani et al., 2013). The current option for HPV vaccination in men is the
quadrivalent vaccine, Gardasil, which has been licensed for use in men since 2009. In 2011,
Gardasil was approved by the ACIP for use in male adolescents aged 11-21 years for the
prevention of genital warts and anal cancer. This vaccine has been proven to be more than 90%
effective in the prevention of HPV infection (Newman et al., 2013).
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The literature review on HPV vaccine uptake in male adolescents shows the important
association between barriers and supports within primary prevention. Research shows that the
primary prevention of HPV among adolescent males largely depends on the attitudes and
behaviors of primary healthcare professionals, parents, and the adolescent males themselves.
Barriers in any form at any level can lead to hindrances in the proper use of HPV vaccination for
men. The primary challenges that exist for healthcare professionals include individual,
ecological, and cognitive barriers such as doubt, confusion, and concerns regarding vaccine
uptake. In addition, organizational barriers might also exist due to ignorance or financial
restrictions. Restrictions can also come from the society at large in terms of capital and financial
support. Primary healthcare professionals play a very important role in vaccine uptake by
providing appropriate knowledge, recommendations, and resources.
As the nature and extent of these barriers has become apparent through a number of
surveys conducted by various public health organizations, a number of organizations have
extended their support to overcome these barriers. The greatest and most important barrier is
cost, and so support in this direction has resulted in a lot of countries offering the HPV vaccine
free of charge to the target population. Primary healthcare providers also play a very important
role in recommending the vaccine to eligible patients and addressing their questions regarding
HPV infection and vaccination. Other sources of support include state policies, regulatory
bodies, and the U.S. National Vaccine Plan. In the age of technology, maintenance of electronic
health records and ensuring their security and privacy also go a long way in encouraging HPV
vaccination.
The theoretical framework used in this study includes the social cognitive theory (SCT),
social ecological model (SEM), and the public health model. The SCT helps generate an
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interpersonal collective effort in producing the desired result (Bandura, 2001). In the SEM,
health-related behaviors are studied with respect to physical, social, and policy aspects (Baral,
Logie, Grosso, Wirtz, & Beyrer, 2013). The public health model promotes assessment, policy
development, and assurance of public health programs such as vaccination. In addition, it takes
into consideration the host, the agent causing the infection, and the environment in which the
agent thrives (Horvath, Misra, Epner, & Cooper, 2014). A combination of these models has been
used as an evidence-based framework for prevention of HPV infections.
Guiding Theory and Framework
Health behavior theories are pertinent in offering a framework for guiding the
development of such an intervention. The SCM were selected to guide this intervention within
interpersonal level within the social ecological model. With the findings of this research, public
health authorities will be in a position to develop outreach programs, campaigns, and policies
that will eliminate the factors identified and so enhance the efficiency of public health
organizations in delivering the HPV vaccine to male adolescents (Dunne et al., 2011).
It is ethical for primary healthcare providers to create awareness in their workplace to
help to prevent HPV-related morbidity and mortality among adolescent males. Previous studies
have focused on the roles of healthcare providers in helping young women to understand the
preventive healthcare they require (Weiss et al., 1997). This study highlights these past findings
and adds to the information already available.
These theories were used as roadmaps that help in guiding the development,
implementation, and evaluation of this research study. In addition, they aid in comprehending
current behavior of healthcare providers regarding their inclination toward HPV vaccine
recommendation to adolescent males (Glanz, Rimer, & Viswanath, 2008). The social cognitive
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theory was used to understand the interpersonal level of healthcare providers’ inclinations in
recommending the HPV vaccine for adolescent male clients. These theories are embedded
within the public health framework and context.
The Social Cognitive Theory (SCT) and the Social Ecological Model (SEM)
The SCT (Rotter & Bandura, 1996 as cited in Glanz, Rimer, & Viswanath, 2008) is built
on the earlier social learning theory (Miller, Dollard, & Rotter, 1954 as cited in Glanz, Rimer, &
Viswanath, 2008). The SCT is a dynamic theory that emphasizes reciprocal determinism—a
concept that recognizes that primary healthcare providers, the healthcare industry, and the
regulatory environment are all interconnected. According to Bandura, the primary healthcare
provider’s behavior will be influenced by vicarious experience or observing the behavior of other
healthcare providers (Andresen et al., 2010 as cited in Glanz, Rimer, & Viswanath, 2008).
The SEM also suggests that there are associations among healthcare providers,
community organizations, and societal policies. Therefore, providers’ inclinations in
recommending vaccination among male adolescents can be influenced by various constructs
such as collective efficacy, observational learning, incentive motivation, facilitation, selfregulation, and policies (Glanz et al., 2008). As such, this intervention will also seek to identify
support that will enhance the goals of primary healthcare providers in recommending HPV
vaccination among adolescent males.
Employing the Public Health Framework in the Research
Understanding the relationship between a healthcare provider’s inclinations in
recommending HPV vaccines and the rural community they serve is important within this
research and could be used to accomplish the public health goal of preventing poor health
outcomes among underserved and rural communities in southwest Georgia. Public health’s
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primary prevention objective is to intervene and seek to prevent disease before it begins. That is
a core tenet of this research in missed clinical opportunities for providers to recommend HPV
vaccination in southwest Georgia.
This study is pertinent to the public health framework because it aligns with public
health’s core functions that are necessary to maintain public health (assessment, policy
development, assurance) and the deliver essential public health services that include:
-Monitoring health status to identify community health problems
-Diagnosing and investigating health problems and health hazards in the community
-Informing, educating and empowering people about health issues
-Mobilizing community partnerships to identify and solve health problems
-Developing policies and plans that support individual and community health efforts
-Enforcing laws and regulations that protect health and ensure safety
-Linking people to needed personal health services and assuring the provision of health
care when it might otherwise be unavailable
-Assuring a competent public and personal healthcare workforce
-Evaluating the effectiveness, accessibility, and quality of personal- and population-based
health services.
(CDC, 2013)
The study also will add to the knowledge base concerning HPV vaccinations that will
help to reduce the burden of HPV-related diseases in terms of mortality, morbidity, and financial
cost. Human papilloma virus is the most common sexually transmitted disease in the US and
causes an estimated 26,000 HPV-cancer related illnesses in the each year. The CDC estimates
the US spends $8 billion on the prevention and treatment of HPV-related diseases (CDC, 2013).
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Public health authorities are actively targeting the adoption of a preventive healthcare
approach to deal with serious diseases such as HPV-related cancers. The campaign to create
awareness about HPV and its effects on human health has received a great response in terms of
the number of males looking to get HPV vaccinations. Primary healthcare providers are
encouraged to ensure that they recommend the vaccine to all young males who seek medical
attention in their facilities. Greater awareness about the virus and HPV-related cancers is one of
the most reinforced messages in the campaign for cancer prevention. The Centers for Disease
Control’s Advisory Committee on Immunization Practices (ACIP) is keen to promote the
delivery of the vaccine for all young adolescents in the United States. Cancer is not selective
based on social class; thus, an effective program must be developed to solve the numerous
barriers to reaching people in these rural areas with the HPV vaccine (Caskey, Lindau, &
Alexander, 2009).
This research provides a framework with which to identify barriers and support the increase of
provider recommendations of HPV vaccination in rural areas (Brewer et al., 2011). It is
important for primary healthcare providers to create relevant awareness in their workplace to
help to prevent HPV-related infections among adolescent males. Previous studies have focused
on the roles of providers in helping young women to understand the preventive healthcare they
require (Weiss et al., 1997). This study will highlight these past findings and aims to add to the
information already available.
Although two HPV vaccines (Gardasil and Cervarix) entered clinical trials in the 1990s,
literature on the subject of this research remains inadequate. Most of the literature available
concentrates on vaccine uptake in females. One reason for this could be that female vaccination
is given higher priority than male vaccination. This study concentrates on the attitudes and
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barriers perceived by healthcare professionals and parents that hinder HPV vaccination of
adolescent males, and the supports available for overcoming these barriers.
Barriers Related to HPV Vaccination
The various barriers related to HPV vaccination in adolescent males are listed below.
Informational Barriers
The greatest barrier to HPV vaccination is ignorance – lack of information and education
among adolescent males, their parents, and healthcare professionals (Chan, Cheung, & Chung,
2007; Hoover et al, 2000). Most people are unaware that HPV infections can be dangerous and
are directly associated with cancers such as penile, oropharyngeal, and rectal.
In one study, Chinese mothers of adolescent children were given an information
pamphlet to analyze if there was a change of opinion towards HPV vaccination after obtaining
the information from the pamphlet. Before reading the information pamphlet, 32% of women
were found to support HPV vaccination for their children. After reading the pamphlet, however,
56% of the women surveyed changed their minds about HPV vaccination from disagreement or
indecision to agreement. Out of these women, 79% accepted that their earlier indecision or
disagreement towards HPV vaccination was due to a lack of knowledge about HPV infection and
its potential risks. The second most common reason for not being supportive of HPV vaccination
was due to fearing the potential side effects of the vaccine which indirectly stem from lack of
information (Chan et al, 2007).
In another study among French women, 76.2% were aware of HPV vaccination;
however, only 16.9% were aware that HPV infection in women could lead to cervical cancer. (In
France, cervical cancer is the tenth most common cancer in women.) Among the women
surveyed, only 54.3% were in favor of HPV vaccination, 0.9% were against it, and 37.2% were
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undecided about the necessity for vaccination. Also, 14.1% of the participants said that they
would rely on their healthcare provider’s judgment. The survey showed that few people were
aware of the recommended ages and the target population for HPV vaccination. Further, only
16% said that they had obtained information about the vaccine from their physician; 54.7% had
heard about it on television (Haesebaert et al., 2012).
In southern Australia, out of 2,000 people questioned, only 40 people were aware of the
cause of HPV infections (Marshall, Ryan, Roberton, & Baghurst, 2007). Another study found
that about 33% of parents in the Netherlands were aware of HPV, and only 15% were aware of
the link between HPV and cancer (Lenselink et al., 2008). A survey of 37 healthcare
professionals in New Mexico found that lack of knowledge about HPV prevented them from
counseling parents about HPV vaccination.
In the rural setting of Appalachian Ohio, among 25% of the people surveyed in this
region, lack of knowledge was a very important barrier to HPV vaccination (Oldach & Katz,
2012).
Among 10th grade students in Germany, 63.6% of the children knew that HPV infection
was sexually transmitted. However, only 41% of the children had received the recommended
three doses of HPV vaccine. It was observed that children who had received at least one dose of
the vaccine were more supportive of HPV vaccination than children who had not received even
one of the three doses of HPV vaccine. The study also found that the information status about
HPV vaccination was lower among boys than girls. This was thought to be due to the fact that
educational campaigns about HPV vaccination are targeted towards girls rather than boys and
hence boys were unaware of the dangers and risks of HPV infection. It was also seen that
vaccinated individuals were more knowledgeable about HPV infections than unvaccinated
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children, and this was thought to be due to information provided to the child and his/her parents
about HPV infections prior to vaccination. The preferred sources of information about HPV
infections among the children surveyed were their healthcare provider and their parents. It is
ironic to note that the most common reason for not being vaccinated was reported to be
dissuasion coming from their physicians and/or parents. Hence, educational campaigns should be
targeted towards healthcare providers and parents of adolescent children (Stocker, Dehnert,
Schuster, Wichman, & Delere, 2013).
A study among male college students found that most relied on information about HPV
from commercials or advertisements or obtained information from their friends, or relied on
news programs and health education programs. The most common sources were considered to be
the television and the internet. Hence, the sources of information for most people about HPV
infection and potential risks are not reliable. The college students were found to be highly
uninformed about HPV and only 4.5% expressed concerns about acquiring HPV infection (Katz,
Krieger, & Roberto, 2011).
In a study conducted among females attending Florida State University, knowledge about
HPV infection was found to be moderate. Factors that affected the variation in HPV knowledge
among these people were found to be Latin ethnicity, incidence of premarital sex, number of
sexual partners, HIV testing, and history of cervical dysplasia. Sexually active people with more
than one sexual partner had more knowledge about HPV than those who are opposed to premarital sex. Television commercials also worked positively to provide information about HPV
vaccination. It was observed that 84% of the participants were aware of the link between HPV
infection and cervical cancer. However, only 30% of the participants were aware that HPV
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infection could also lead to genital warts. Sixty percent of the participants also incorrectly
thought that HPV infection could lead to ovarian cancer (Gerend & Shepherd, 2011).
The acceptability levels of HPV vaccination among people in sub-Saharan African
countries were found to be high in a study conducted there; however, knowledge about HPV
infection and vaccination was low. Given that cervical cancer in women is among the leading
causes of mortality in this region, the reach of vaccination programs is surprisingly low (Perlman
et al., 2014). A lack of knowledge among the people in this region has resulted in an overall
negative opinion regarding the safety of the vaccine, along with concerns regarding possible side
effects. Due to serious concerns about the health of women in this region, a number of strategies
have been proposed to educate the people in this region thereby increasing acceptability levels.
Some of the proposed methods include HPV vaccination pilot programs, clinic- and schoolbased vaccination programs, community outreach programs in churches, sensitization
campaigns, educational campaigns to targeted groups such as doctors, nurses, midwives, and
healthcare workers, and awareness through social media and mass media (Perlman et al., 2014).
It is heartening to note that, according to a study conducted in Vietnam, a large portion of
the population there is supportive and convinced that HPV vaccination is beneficial. The study
also found that the people largely trusted information provided by educational campaigns
conducted by the government, as they believe that the government would do nothing to harm
people’s health (Cover et al., 2012).
According to a 2012 study conducted by Bartolini, Winkler, Penny and LaMontagne in
Peru, if adequate information was available to the people from credible sources, most of the
parents did get their adolescent children vaccinated. Sources that had the most effect on the
parents’ decision-making process were teachers and healthcare providers. This clearly
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demonstrates that information campaigns will go a long way in ensuring HPV vaccination of the
entire target population (Bartolini et al., 2012).
Research has shown that a very important factor in changing the mindset regarding HPV
vaccination is community sensitization meetings with parents. This has been proven to work
better in rural areas than in urban areas. These meetings were found to be intense educational
sessions for the parents, and they also found good information in the consent forms. These
meetings also allowed them to ask questions, and to voice their fears and concerns. Some people
said that they heard about the vaccine for the first time in these meetings. A few others also
reported that they had made a decision to get their children vaccinated against HPV based on the
discussion that took place in the meeting (Bartolini et al., 2012).
Another example of an information campaign about HPV vaccination is a multi-level,
multimedia communication campaign implemented in Peru via radio stations, the local Catholic
Church, press, television, and posters and banners used in health facilities and schools. Many
people reported that, after having seen or heard these news items, they decided to go ahead and
have their children vaccinated (Bartolini et al., 2012).
Lack of proper information about HPV vaccination can hugely affect the efforts of the
government and health organizations to protect against HPV infections. Thus, educational
campaigns and interventions about HPV have been highly recommended for parents and
healthcare professionals.
Safety and Efficacy Barriers
Safety concerns about the HPV vaccine are another important barrier for both parents and
healthcare workers. In a study conducted in the Netherlands, 1,367 participants had concerns
about the safety and efficacy of the vaccine. This concern acts as a huge barrier to vaccine uptake

25
(Korfage, Essink-Bot, Daamen, Mols, & van Ballegooijen, 2008). Another study involving
pediatricians found that the same concern prevented them from providing appropriate counseling
to parents (Kahn & Bernstein, 2005). This concern could also be a byproduct of a lack of
information as studies sufficiently prove the safety of HPV vaccines such as Gardasil (Gudeman,
2007). Concerns about the vaccine are also centered on potential side effects (Gerend, Lee, &
Shepherd, 2007; Marshall et al., 2007; Woodhall et al., 2007).
It is readily apparent that these concerns indirectly stem from lack of information. This is
true because the safety and efficacy of both HPV vaccines (Gardasil and Cervarix) have been
proven time and again through studies and clinical trials. It has been shown that both of these
vaccines prevent infection with HPV types 16 and 18, which are responsible for 70% of all
cervical cancers. Data from clinical trials show that these vaccines are 90-100% effective in
preventing the formation of precancerous cervical lesions due to infection with HPV types 16
and 18 (Fernandez, Allen, Mistry, & Kahn, 2010).
Clinical trials of both vaccines conducted in different parts of the world have shown that
the clinical endpoints include cervical intraepithelial neoplasia (CIN) 2/3, adenocarcinoma insitu (AIS), and anogenital warts, which are considered to be precursors to cervical cancer. Data
from a large number of international, randomized clinical trials prove the immunogenicity and
efficacy of both these vaccines. Gardasil is also shown to prevent anogenital disease caused by
HPV types 6 and 11. Clinical trials and post-marketing safety monitoring measures have shown
that both the vaccines are reasonably safe and well-tolerated. This has been further supported by
data from the Center for Disease Control and Prevention (CDC) in the US, and the World Health
Organization (WHO) Global Advisory Committee on Vaccine Safety. The CDC has also
conducted post-licensing studies to evaluate the safety of Gardasil, and no adverse events have
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been seen to occur due to the vaccine. Despite these studies and trials, there are still a great
number of people who have concerns about the safety of these vaccines, and hence refrain from
having their children vaccinated (Fernandez et al., 2010).
Studies have effectively shown that because both of the HPV vaccines, Gardasil and
Cervarix, are comprised of non-infectious virus particles, the vaccine in turn is non-infectious
and safe. Both vaccines have been shown to elicit strong antibody responses, thus proving their
efficacy. It has been noted, however, that the vaccines are not very effective in people who have
already acquired HPV infection through sexual contact. Hence, it is important that children get
vaccinated against HPV before they reach sexual maturity. Regarding safety of the vaccine,
studies show that the most common side-effects after HPV vaccination include erythema, pain at
the injection site, and swelling. One serious consequence of HPV vaccination was that a small
number of women who became pregnant within 30 days of vaccination underwent spontaneous
abortion. If a woman gave birth after conceiving within 30 days of vaccination, the children were
found to have congenital abnormalities. This further reinforces the fact that adolescents should
get vaccinated against HPV before commencing sexual intercourse (Moscicki, 2008).
Another concern for parents was that it would send the wrong message to their children
regarding sexual practices or age for initiation. A study conducted among healthcare providers in
Texas found that about 50% parents were averse to HPV vaccination due to concerns regarding
safety, negative media reports, and the concern that vaccination would encourage premarital
intercourse (Fernandez et al., 2010).
Among 10th grade students in Germany, about 30.8% of the participants were
unvaccinated due to concerns about the vaccine’s safety and potential side effects. About 9% of
the participants also considered the HPV vaccine to be relatively new and that more research was
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needed to explore its safety (Stocker et al., 2013). In France, almost 55% of the participants were
averse to HPV vaccination due to concerns about possible side effects and the newness of the
vaccine. Another factor was distrust that stemmed from a controversy, also in France, regarding
a link between hepatitis B vaccination and multiple sclerosis after a mass hepatitis B
immunization campaign in 1994 (Haesebaert et al., 2012). Similar trends are observed in highincome countries such as the UK and the US where people have trust issues regarding a
vaccine’s safety in addition to questioning the motives of pharmaceutical companies and
governmental health agencies in promoting vaccination. People also fear that the vaccine will not
be effective long term. These people tend to have issues with all vaccines and find it difficult to
come to terms with the fact that a vaccine is an inactive form of an infectious organism (Ferrer,
Trotter, Hickman, & Audrey, 2014).
On the bright side, among the people of Denmark, attitudes towards HPV vaccination
were mostly positive and arose from a general confidence in the safety and efficacy of the
vaccine. However, a lot of parents expressed the need to have more information about the action
and safety of the vaccine before proceeding with vaccination. A majority of the parents were not
worried about vaccination encouraging unsafe sexual practices as they believed that both men
and women were responsible for taking care of their health and protecting themselves from
sexually transmitted diseases (STDs) (Mortensen, 2010).
In Hong Kong, 51.2% of the people regarded vaccine safety as an important criterion for
choosing a vaccine. The other criteria were strength of protection, life-long immunity, and a
good antibody response. Even among physicians, the same trend was observed. As many as
78.6% of adolescents reported that their parents refused to get them vaccinated against HPV due
to safety concerns (Wong, Lee, Ngai, Chor, & Chan, 2013).
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In Canada, only 65.1% of parents agreed to have their children vaccinated against HPV,
as opposed to 85% who agreed to vaccination for hepatitis B and meningitis C. Almost 50% of
those who had agreed to HPV vaccination said that their main reason for consent was belief in
the effectiveness of the vaccine. On the other hand, about 33% of the parents who were against
HPV vaccination said that their main reason for not agreeing to have their children vaccinated
was concerns regarding the safety of the vaccine. About 46.3% of the parents who were against
vaccination also said that if they had more data about the safety of the HPV vaccines, they would
be able to make an informed decision regarding vaccination (Ogilvie et al., 2010).
This barrier has a lot of implications for HPV vaccine policies, as it is not a financial or
organizational barrier that can be dealt with on a single level. Although vaccine programs are
fully funded as a part of school-based immunization programs in a many countries, almost 35%
of the parents choose not to have their children vaccinated due to safety and efficacy concerns. In
a study conducted in Manchester, UK, parents identified vaccine safety as a major factor for not
supporting HPV vaccination. This trend is true for a large number of regions around the world
according to studies conducted in these places (Ogilvie et al., 2010).
Efforts to overcome this barrier have been implemented in a number of places. One
example is British Columbia, Canada, where vaccine education programs were conducted to
address vaccine safety and efficacy issues via a number of platforms such as the
www.immunizeBC.ca website, distribution of two sets of DVDs highlighting the safety of HPV
vaccines—one set for parents and the other set for adolescents—and pamphlets, brochures, and
local information sessions for both parents and healthcare providers emphasizing the safety and
efficacy of both HPV vaccines. Also, the Canadian National Advisory Committee on
Immunizations was involved in strongly recommending this vaccination for adolescents. Despite
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these efforts, it is distressing to note that a lot of parents were undecided about HPV vaccination
and reported that they needed more information to come to a decision (Ogilvie et al., 2010).
Psychological Barriers
Psychological barriers are comprised of personal or emotional discomfort regarding HPV
vaccination. These barriers can be from the side of the healthcare professionals regarding
interactions with parents or guardians (Dempsey & Davis, 2006; Kahn & Bernstein, 2005;
Sussman et al., 2007), or from the side of parents and adolescent males regarding the
encouragement of promiscuity due to HPV vaccination (Marshall et al., 2007; Woodhall et al.,
2007). Such barriers could also arise from lack of knowledge or cultural barriers of the patients.
In Ireland, an attempt to understand the general practitioners’ and nurses’ attitudes
towards recommending the HPV vaccine to their patients found that a number of concerns
inhibited them from doing so. Some of those concerns included starting a discussion about HPV
infection with their female patients, appropriateness of the situation in which to offer HPV
vaccination, and addressing patients’ questions regarding HPV. This can hugely affect the
attitudes of the patients towards HPV vaccination for women. Their GP’s attitude influences
their own prevention behaviors. Most healthcare providers surveyed said that it was easier to talk
about HPV with their patients if the discussion was indirectly started by them in terms of Pap
smear testing or risk factors for cervical cancer. These providers rarely performed a routine HPV
tests on their patients. Also, the providers seemed to be influenced by gender differences,
thinking that only women should perform an HPV test for another woman (McSherry et al.,
2012).
According to a study, a lot of practitioners consider the topic of HPV to be “sensitive”
and “awkward” because it relates to sexual practices and the prevention of STDs. There were
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concerns about embarrassment and awkwardness with their patients. This made the practitioners
beat around the bush with regards to this topic or avoid it altogether. Another factor was patients’
reluctance to discuss the topic due to social influences. They were also worried about the
consequences if the topic of HPV was raised and the patients might subsequently avoid Pap
smear testing altogether. A number of nurses said that if they raised the topic of HPV with their
patients, they would consider it as passing judgment on their sexual practices and this would be
considered professionally inappropriate. The providers’ concerns about the appropriateness of
the topic might not be completely without reason as a survey conducted in Ireland found that
women were reluctant to go for Pap smear testing as they considered it a sign that they were
sexually active. Also, when women found out about the link between HPV and cervical cancer,
they “were shocked, angry, and felt that this was a ‘secret’ that the medical community had kept
from them” (McSherry et al., 2012).
A study that aimed to examine the effects of gender bias on the decision to go for HPV
vaccination found that women who are less educated, older, uninsured, homeless, migrants,
lesbians, obese, or have language problems are less likely to go for Pap smear testing. In China, a
woman is considered inferior to a man, and so women are generally deprived of medical health
facilities and regular checkups. Also, women who are lesbians often have to deal with the fear of
discrimination and hence, shy away from taking medical advice or initiating discussions about
the risks of unhealthy sexual practices. A survey in Canada found that lesbians have a much
poorer health status as compared to heterosexual women. This result is true for the US and the
UK as well: “In the UK, lesbian women are more likely to avoid screening than heterosexual
women, and more likely to have never attended screening than American lesbian women.” In the
UK, it has been seen that negative Pap smear test results can lead to stigma, guilt, and
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embarrassment, and might work negatively in having the patient go for treatment (Brankovic,
Verdonk, & Klinge, 2013).
Another study analyzed the perceptions and beliefs of mothers of 11 to 12-year-old
children had concerning whether or not to get an HPV vaccination. Factors influencing this
decision included parents’ experiences and beliefs regarding vaccination in general, discussions
with healthcare providers, friends, and family members regarding HPV infection and
vaccination, and information provided by media about HPV vaccination. However, it was found
that “mother’s health-related beliefs and experiences were the most frequently noted factors in
the decision to vaccinate daughters.” Regarding the age group for which the vaccination is most
appropriate, one mother noted that “I feel if it’s gonna protect her when she becomes sexually
active, do it now. Because with today’s day and age you never know when they’re going to start
having sex.” Other positive influences came from a family history of cancer, HPV infection, or
other STDs (Griffioen et al., 2012).
Factors that affected the uptake of HPV vaccination included perceptions about what
others thought about HPV vaccination, discussion with adolescents regarding HPV infection and
its mode of transmission, knowledge about a patient’s sexual history, and discomfort in talking
about HPV with female patients. The study found that about 10% of pediatricians were unlikely
to recommend the vaccine to their patients, and only 46% of the providers were ready to
administer the vaccine to their patients. Factors that help patients choose to get vaccinated
against HPV include HIV testing in the past, having multiple sexual partners either in the past or
present, a family member suffering from cancer, and level of acceptance of the vaccine in the
family (Gamble et al., 2010).
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Another study found a relationship between emotional responses and societal influences
and the decision to get vaccinated against HPV. Most of the participants said that their emotional
responses on hearing about HPV varied from shock to concern, depending on how the
information was given to them. They seemed to think that talking about vaccination against HPV
was more likely to invoke positive reactions than dwelling on the link between HPV and cervical
cancer. They thought that the general perceptions and beliefs of the society regarding HPV
vaccination also depended on how the information was put across to them. This was because
talking about vaccination provided them with a way to prevent cervical cancer in the future
rather than judging their current sexual practices and scaring them about HPV infections, STDs
and cervical cancer (McRae, Martin, O’Leary, & Sharp, 2014).
Other factors that were important in having the practitioners discuss HPV with their
patients included their concerns about the safety of the vaccines, having or not having daughters,
negative media publicity about HPV, personal thoughts and beliefs about vaccination in general
and HPV vaccination in particular, embarrassment in not being able to answer patients’ questions
correctly, and considering it inappropriate to talk about sexual issues with their patients
(McSherry et al., 2012).
Among the Dutch, the attitudes and perceptions towards HPV vaccination were
influenced by factors that included religious beliefs, perception of risks associated with
vaccination, expectations of either positive or negative outcomes, anticipation of regret after
vaccination, opinions about alternative medicine, and confidence levels in the authorities
promoting HPV vaccination. Beliefs such as “The HPV vaccination was only introduced because
the pharmaceutical industry will earn a lot of money from it,” “My daughter is too young to
receive the HPV vaccination,” and “My daughter does not need to get the HPV vaccination if she
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is already sexually active” had a very strong influence on peoples’ decision regarding HPV
vaccination. The perceptions and beliefs of friends, general practitioners, physicians, nurses,
people from the municipal health service and the Ministry of Health, spouses, parents, and other
family members mattered when deciding whether or not to vaccinate children against HPV
(Keulen et al., 2013).
A major cause for concern is parental beliefs that getting their child vaccinated against
HPV will encourage risky sexual behaviors. Apart from this, conservative religious views, moral
issues about sexuality, not considering their child to be at risk for acquiring HPV infection,
previous negative experience(s) with vaccination, and parent-child communication about safe
sexual practices also influence parents’ decision to get their children vaccinated against HPV
(Gamble et al., 2010).
All these studies point toward an emerging need to provide support to healthcare
providers in discussing HPV infection and vaccination with their patients. Efforts should be
targeted towards both male and female healthcare providers and should help them in discussing
HPV with their female patients, recommending HPV vaccination in appropriate cases, and
answering patients’ questions about HPV (McSherry et al., 2012).
Cultural Barriers
Cultural barriers such as race, ethnicity, socioeconomic status, education levels and
health insurance status can stand in the way of HPV vaccination (Sussman et al., 2007).
According to Daley, “Across racial/ethnic groups, factors associated with vaccine acceptance
among men include knowledge of HPV, perceived threat, and perceived barriers to HPV
vaccine” (Daley et al., 2011).
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This barrier is important because studies show that Black and Hispanic people are more
often diagnosed with HPV-related cancers than people belonging to other ethnicities. It has been
noted that Hispanic people have stronger intention to go for HPV vaccination than non-Hispanic
people; however, very few Hispanic people have access to a healthcare facility where they could
actually get vaccinated. Also, after informational sessions, about 43% of the people belonging to
minority groups said that they were unable to grasp or comprehend the information completely.
A survey conducted in 2007 showed that only 1% of Hispanic women had acquired at least one
dose of the vaccine (Daley et al., 2011).
A study of people of Hispanic origin in New Mexico showed that healthcare
professionals had to consider cultural beliefs of the patient with respect to HPV infections and
vaccination before recommending the vaccination to them (Vanslyke et al., 2008). For example,
most Hispanics, as a result of their cultural beliefs, do not use condoms during sexual intercourse
and thus can expose their partner to the risk of HPV infection. Another study found that
healthcare professionals also had concerns regarding their patients’ strong religious views or
beliefs about healing or general distrust of healthcare facilities (Tissot et al., 2007).
A very important factor that can serve as a barrier to HPV vaccination is social beliefs
and values, particularly those relating to sexual practices and behaviors. These concerns were
found to influence healthcare providers in recommending the vaccine to parents of adolescent
children. On one hand, they were more inclined to recommend the vaccine if they suspected
people of belonging to a group where sexual intercourse with multiple partners was common;
however, they seemed to be reluctant to discuss sexual issues with their more conservative
patients. This also acted as a deterrent to many parents who did not want to discuss sexual issues
with their children or who did not want to accept that their children will soon become sexually
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active and the importance of protecting them against sexually transmitted diseases (STDs)
(Ferrer et al., 2014).
An interview with a school nurse in Sweden revealed that when people belonged to a
strict cultural background where premarital sex is taboo, it was difficult to talk to them about the
dangers of intercourse with multiple partners. They felt that if this vaccination was given to their
children, they would get the wrong signal regarding sexual practices and this would encourage
them to try intercourse before marriage. This is also true for religious faiths that are strictly
against premarital sex and hence do not consider this vaccination necessary. In these scenarios, a
concern for adolescents is that if they talk about this vaccination, their parents and family
members might think that they are having illicit sexual relations (Ferrer et al., 2014).
Women in Hong Kong also have similar concerns about HPV vaccination and premarital
sex. They also see the HPV vaccine as a potential threat to the health of their children and
consider it unnecessary. This attitude also arose due to the lack of fruitful discussions regarding
the necessity and efficacy of the vaccines with their healthcare providers (Siu, 2014).
The perceptions of African Americans toward HPV vaccination included a number of
barriers that prevented them from taking the step. However, the fear of their children initiating
sexual intercourse after vaccination was not very prominent. They believed that children will
engage in sexual relations whenever they feel ready and it has nothing to do with their
vaccination status. Religious issues were also not a problem here as they felt that religion had its
own place in one’s life; however, it should not bear upon the decision to take care of one’s health
(Thompson, Arnold, & Notaro, 2012).
The attitudes of Latinas towards HPV vaccination are important because Latinas usually
present with higher rates and severity of cervical cancer compared to non-Latinas. It was found
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that only 59% of the participants thought that HPV vaccination could effectively prevent HPV
infection. The Latinas’ lack of knowledge and awareness about HPV could be attributed to
“lower education, low English language acculturation, and lack of exposure to media messages”
(Luque et al., 2010).
Among girls belonging to ethnic minority groups, ethnic differences played a very
important role in awareness about HPV and other beliefs regarding immunization. Only 63% of
the surveyed people had even heard about HPV and only 12% had been vaccinated against HPV.
It was also seen that African Americans and Chinese participants were not very supportive of
including the HPV vaccine in a school-based immunization program. A huge barrier for these
people was lack of information about HPV and its associated risks. A few participants also had
concerns that it would negatively damage their child’s health or lead to fertility problems in the
future (Bastani et al., 2011).
The prevalence of HPV vaccination among minority groups in the UK showed that the
uptake of vaccination varied by ethnicity – the highest rates were observed among Asians,
followed by White people and finally Black people. The rate of acceptability of the vaccine was
76% among White people compared to 61% among non-White people. The lowest levels of
acceptance (11-24%) were seen among South Asian parents. Religious beliefs about not having
premarital sex also played a role in influencing parents’ decision regarding HPV vaccination
(Marlow, 2011).
Another study found differences in HPV vaccination status vary with ethnicity. This
study showed that the chances of African American women going for vaccination were much
lower than those of White women. Also, Asian women were less inclined towards HPV
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vaccination compared to White women (Fisher, Trotter, Audrey, MacDonald-Wallis, &
Hickman, 2013).
Some healthcare providers feel reluctant to talk to ethnic minority groups about
vaccination if they feel it would go against the patient’s culture. There is additional resistance
due to the Tuskegee syphilis experiment in which African Americans in the USA were used for
studying the progression of syphilis without their knowledge or consent. Hence, a number of
minority groups mistrust the motives of healthcare professionals in recommending vaccination
(Ferrer et al., 2014).
Studies also show that women coming from low-family-income households are less
likely to complete their HPV vaccination course. Also, women coming from deprived
households were more often not HPV vaccinated (Fisher et al., 2013).
Barriers are not seen only in the low-income groups or people who do not have access to
information. A low level of compliance for HPV vaccination is also observed among people who
have a high income and access to good educational facilities. These people have been observed
to give little importance to the risk of acquiring HPV infection and hence they do not consider it
necessary to go for vaccination (Hopenhayn, A. Christian, Christian, & Schoenberg, 2007;
Woodhall et al., 2007). Some healthcare professionals in the US feel that HPV is not an infection
that could be transmitted or prove dangerous in a school setting and hence believe it is not
necessary to introduce HPV vaccination as part of school-based immunization programs.
According to a pediatrician in US, “It would not be a school or a public-health issue, but more of
an individual issue.” This further reduces the convictions of parents that HPV vaccination is
necessary for their children (Ferrer et al., 2014).
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Gender is another issue as most of the marketing strategies and informational campaigns
have concentrated on women, making men feel unsure about the necessity of the vaccination.
Most people feel that HPV infection is a “woman’s disease” and is not relevant to men, and so
do not think about the vaccination for their adolescent male children (Daley et al., 2011).
Healthcare providers have taken a number of measures to overcome these cultural
barriers by bringing in more bilingual and bicultural staff, concentrating on recruitment of
diverse staff, and reaching out to minority groups through their community organizations (Daley
et al., 2011).
Financial Barriers
Gardasil, which is an HPV quadrivalent (types 6, 11, 16 and 18) recombinant vaccine, is
the most expensive vaccine recommended for genital warts, being priced at $360 for the total
regimen (Gudeman, 2007). Research shows that health insurance does not cover the entire cost
of the vaccine (Hopenhayn et al., 2007). Hence, the financial constraint coupled with lack of
information makes it difficult for people to make an informed decision.
Although low-income women are more likely to develop cervical cancer, they are much
less likely to complete the HPV vaccination course than high-income women (Vadaparampil et
al., 2013). A study of low-income participants found that only 58% of them could afford the
entire cost of the vaccine. Thus, most of the women would go for the first dose after an intense
discussion with a practitioner or an informational session about HPV vaccination; however, the
high cost of the vaccine slowly eats away the motivation to go for the second and third doses
(Kahn et al., 2008). Another study found that cost was a huge barrier to vaccination. Participants
in the 18-22 age group said they were unlikely to go for vaccination if they had to bear the costs.
Most of them only got vaccinated because their parents paid for it (Mortensen, 2010).
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The same trend was seen even in high-income countries like the US. Participants in U.S.
said that the cost of HPV vaccination was $135 for each of the three injections and this was
either partially covered or not covered by insurance (Ferrer et al., 2014). Another study found
that about 24.4% of people considered insurance coverage and 14.6% considered cost to be a
deciding factor in the decision to acquire vaccination against HPV (Zimet, Weiss, Rosenthal,
Good, & Vichnin, 2010).
The financial burden also falls on the healthcare providers in buying the vaccine because
of the chance that patients might not buy the vaccines from them (Dempsey & Davis, 2006). In
the US, healthcare providers face a huge financial burden in providing HPV vaccines to their
patients in terms of money as well as time. According to a practitioner in the US, “There is no
way vaccines are cost-effective for us. It costs the US an incredible amount of money in terms of
time.” Other financial concerns include high costs of buying vaccines in bulk, lack of healthcare
insurance, and insufficient reimbursement by the insurance companies (Ferrer et al., 2014). One
study found that 36.5% of the physicians considered cost of stocking vaccines as a barrier, 47.4%
considered inadequate reimbursement a barrier, and 40.2% considered lack of timely
reimbursement a barrier in buying and recommending HPV vaccines (Malo et al., 2013).
Practitioners in Sweden were reluctant to bring up the topic of HPV vaccination with
their patients if they felt that the patients couldn’t afford it. They considered it an ethical issue
and against their morals to put their patients in a position where they were forced to spend a large
amount of their money on something their practitioner thought was important, but not
immediately vital. This hugely deterred practitioners from talking about HPV infection and
vaccination with their patients (Ferrer et al., 2014).
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Most people are not ready to pay more than $100 for the HPV vaccine. About 70% of the
participants reported cost to be a barrier for HPV vaccination (Daley et al., 2011). Another study
found that about 41.3% of the participants were less likely to go for HPV vaccination due to the
high costs (Patel et al., 2012).
In the US, only 56% of the people who took the first dose of the HPV vaccine went on to
complete the course. The reasons for not completing the series included lack of insurance and
low family income. About 76.4% of the participants said that they wanted it at a lower cost or at
no cost, compared to only 20% of the participants who were ready to pay the entire cost of the
vaccination (Laz, Rahman, & Berenson, 2013).
In India, Gardasil has been introduced at a cost of $171 for three injections and thus it
remains largely out of reach of most middle- and low-income families. Countries such as India
have considered the possibility of local production of the vaccines at reduced costs. However,
issues such as patents and technology can become a hurdle for this kind of advancement
(Padmanabhan, Amin, Sampat, Cook-Deegan, & Chandrasekhran, 2010).
Many people in Hong Kong are deterred by the high cost of the vaccine. In Hong Kong,
the vaccine costs between $321 and $514 US. The fact that the vaccine was not included in the
government’s child vaccination scheme influenced people to think that it was an unnecessary
expense. People in Hong Kong are of the mindset that the extremely important vaccines would
be available free-of-cost (Siu, 2014).
As most of the marketing efforts of pharmaceutical companies manufacturing HPV
vaccines have been targeted to women, it is not surprising to note that a number of immunization
programs are available only for girls. A very important reason for this gender difference is
financial constraints. A study conducted by Pearson et al. in 2014 in the US found that including
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adolescent boys in school-based immunization programs would be extremely cost-ineffective.
This could only work if the costs of the vaccine and its administration were extremely low. An
initiative by the Australian health authorities in 2013 made HPV vaccination free and available
to boys, and this step has attracted a lot of criticism with regards to its cost-effectiveness
(Pearson et al., 2014).
In Florida, if more physicians participated in the Vaccines for Children (VFC) program,
their financial burdens regarding HPV vaccination would be significantly reduced. A survey
conducted in 2007 found that the amount of reimbursement received for the cost of a vaccine
plays a very important role in recommending the vaccine to a patient, with inadequate
reimbursement resulting in a 55% less likelihood of recommending the vaccine. The VFC
program provides free-of-cost vaccines for children who are eligible for Medicaid, Native
American or Alaskan, or uninsured. This program allows even private practitioners to administer
the vaccine to their patients (Malo et al., 2013)
Statistics show that about 80% of cervical cancer cases are reported from the poorer
nations, and this is due to unavailability of vaccination due to financial constraints (Katz et al.,
2010). A number of countries have begun offering the HPV vaccination free-of-cost as part of
school-based programs or other immunization programs. Australia was the first country to start a
school-based vaccination program for children ages 12-13 years in 2007 (Ferrer et al., 2014).
The Danish National Board of Health started a childhood-immunization program in 2009 for 12year-old girls, and a catch-up vaccination program in 2008 for girls ages 13-15. Women ages 1626 years had to pay 470 euros to get vaccinated (Mortensen, 2010). Similar programs have also
been introduced in the US, the UK, Sweden, and Canada (Ferrer et al., 2014).
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Initiatives have also been taken by the World Health Organization (WHO) through its
Cervical Cancer Prevention and Control Costing (C4P) tool that was developed to improve
accessibility to the HPV vaccine in middle- and low-income countries. This tool has helped
countries get financially prepared for expenses such as service delivery strategies, and largescale transportation of vaccines and health workers in establishing a nation-wide immunization
program. This tool was developed in response to a request for assistance from the Ministry of
Health and Social Welfare (MOHSW) in Tanzania for the estimation of the cost for the
introduction of HPV vaccination in the country. This tool provides a country-specific report on
the estimated costs of additional resources for the incorporation of HPV vaccine to existing
immunization programs over a 5-year time period. Based on estimates obtained from this tool,
1.6 million of the 2.4 million girls in Tanzania had received the complete series of HPV
vaccination over a period of five years. This is similar to other initiatives such as Program for
Appropriate Technology in Health (PATH) in India, Uganda, Peru, and Vietnam, and a program
that the London School of Hygiene and Tropical Medicine (LSHTM) implemented in Mwanza
province in Tanzania (Hutubessy et al., 2012).
Compliance Barriers
The highly recommended HPV vaccine, Gardasil, is a three-dose vaccine requiring the
first, second, and third doses at zero, two, and six months, respectively (McIntosh, Sturpe, &
Khanna, 2008). This often becomes a challenge for people with limited access to transportation
and little ability to take time off work (Herzog, Huh, Downs, Smith, & Monk, 2008). In a study
analyzing the attitudes of people living in Denmark towards HPV vaccination, one of the reasons
that came up for not getting vaccinated was that it was “too inconvenient to have three injections
within six months” (Mortensen, 2010).
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The fact that the vaccine must be kept in cold storage and the number of doses required
were a huge barrier to vaccination programs. According to one of the participants, “reducing
doses and reducing our reliance on the cold chain, those are the general directions we would like
to see it go.” The healthcare providers also seemed reluctant in transporting staff and vaccines
every few days for vaccination programs. The problems they faced were insufficient human
resources in terms of limited health workers and capacity of the staff. According to the providers,
it often becomes a challenge to cover three doses for an entire population (Wigle, Coast, &
Watson-Jones, 2013). Problems also arise at the physician’s end in terms of availability and
scheduling a patient three times for HPV vaccination (McIntosh et al., 2008).
Reaching eligible girls to deliver HPV vaccination is often quoted as a challenge by most
healthcare providers. In the case of school-based vaccination programs, poor planning strategies,
and proper documentation were major hurdles in achieving 100% vaccination rates. According to
one of the people involved in a school-based vaccination program, “It is a big challenge to
adequately and effectively document the accepted names and the numbers of girls who received
dose one, who received dose two, and who received dose three.” A further challenge was to
make sure that even those children who were absent on the day the program took place in the
school get covered (Wigle et al., 2013).
School-based vaccination programs do not work in countries where school enrollment
and attendance are very low. In Uganda, although school-based vaccination programs were
carried out in combination with existing child public health days, only 52.6% coverage was
achieved. In Vietnam, community health-center-based immunization programs proved to work
better than school-based immunization programs (Wigle et al., 2013).
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A small percentage of the people faced problems in going to the health center for three
injections, getting a leave of absence from work or school, and lack of adequate transportation
facilities. Also, only 50% of the participants said that they had a place where they could go to get
vaccinated (Daley et al., 2011). Another study found that women who are at high risk for
cervical cancer do not have access to healthcare facilities mainly due to lack of transportation
(Scarinci et al., 2010).
A disturbing study in Somalia found that most of the patients who initiate HPV
vaccination do not complete it. Also, those who do return for the second and third doses do not
do so in the recommended time interval. The reasons for this have been postulated to be lack of
access to the healthcare system and language barriers (Pruitt, Reese, Grossardt, Shire, &
Creedon, 2013).
Another study conducted in 2013 evaluated the accessibility of healthcare centers for
children living in Los Angeles and if proximity to safety-net clinics had any influence on the
decision to get vaccinated against HPV. This study was inspired by previous studies showing
that lack of access to healthcare services can be an important factor in dissuading people from
undergoing vaccination. The study found that about 90% of Latina girls had easy access to a
healthcare center, compared to 68% of Chinese girls and 70% of Korean girls. Also, it would
take three times longer to go to a healthcare center by public transportation than in a personal
vehicle. Hence, not owning a vehicle and relying on public transport can work negatively in
making a decision to get vaccinated against HPV (Tsui et al., 2013). About 58% of physicians in
Hong Kong reported that it was very difficult to get the patients to visit the clinic for their second
and third doses of HPV vaccination, and 51.8% of the physicians said that the patients
considered it time-consuming to come for multiple doses (Wong et al., 2013).
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Among the people of Appalachian Kentucky, lack of transportation and prioritizing work
and school over health are major barriers to HPV vaccination. According to a participant, “Me
and my fiancé, neither one have a driver’s license, so we don’t have a car… We’re dependent on
my mother to take us [places].” Even people who had access to transportation facilities
considered lack of transportation to be a major barrier. Many women tend to place other
responsibilities like caring for a newborn child over HPV vaccination. Also, full-time work can
take up a lot of time in a person’s life and can lead to neglect of one’s health – “I work six days a
week… from 9 a.m. until 8 p.m. in the evening, so it’s hard to make time for HPV vaccination”
(Mills, Head, & Vanderpool, 2013).
A study conducted in 2011 examined the levels of adherence to the HPV vaccine dosing
schedule. The study found that very few people stuck to the recommended time interval for the
second or third doses; most of them were either early or late for their scheduled visits. The
reasons for not completing the vaccination course were adverse events or side effects after the
first dose of vaccine, and the influence of the attitudes and beliefs of general practitioners or
family members. Other common factors included forgetting about the appointment for
subsequent doses of vaccination, lack of insurance, and inability to take time off work or other
responsibilities (Widdice, Bernstein, Leonard, Marsolo, & Kahn, 2011).
Most practitioners did not find the time during a routine consultation to explain in detail
about the risks of HPV infection and the availability of HPV vaccination to their patients.
According to one general practitioner, “You know, we’re asked to promote diabetes management
and we’re asked to promote smoking cessation and things like that so there’s so many other
things that we’re trying to fit in.” As reported with other studies, practitioners found it difficult to
encourage patients to complete the three-dose schedule of HPV vaccination. Patients often
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simply forgot to return to the clinic for subsequent doses or didn’t have the time to do so (Mazza,
Petrovic, Grech, & Harris, 2014).
One surprising barrier that was found to affect a general practitioners willingness to talk
about HPV vaccination with a patient was the practitioners’ physical work environment. This
included issues such as vaccine availability in the clinic, established routines for vaccine
administration, and availability of nurses for vaccine administration. If the vaccine was not
available on site, it usually became difficult to encourage patients to purchase the vaccine and
come back for another appointment to have it administered (Mazza et al., 2014).
Among college students in Taiwan, situational influences could affect a person’s decision
to go for HPV vaccination (Kuo, Yeh, Sheu, & Wang, 2014). Results from the National
Immunization Survey-Teen conducted in 2009 showed that only 26.7% of the participants had
completed the course of HPV vaccination. Initiatives have been taken to encourage vaccine-only
visits among patients, along with reminders to visit the clinic for the second or third dose of
vaccination (Sudenga, Royse, & Shrestha, 2011).
Initiatives such as making the vaccine available at community locations such as Walmart
and community colleges have been considered. A lot of people seemed supportive and thought
that it could do away with barriers such as access to transportation and everyday responsibilities
(Mills et al., 2013). In order to address the issue of patients not returning for subsequent doses of
HPV vaccination, efforts to establish a recall system or contact patients via practice nurses are
under way (Mazza et al., 2014).
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Supports Related to HPV Vaccination
The following supports are available for HPV vaccination in adolescent males.
Financial Supports
In accordance with the recommendations for HPV vaccination and faced with alarming
rates of HPV infection and cervical cancer, many countries have taken steps to encourage people
to go for HPV vaccination. The first step was taken by Australia, when it started offering a
school-based vaccination program in 2007 for all girls age 12-13 years. This was soon followed
by other countries including the UK, Sweden, and Canada. In the US, young women who are
eligible for insurance through Medicaid, are uninsured, or underinsured can get vaccinated
against HPV free-of-charge. However, school-based immunization programs are still in the
discussion phase in the US as, according to Ferrer, “policy makers in the USA were not clear that
a school-based mandate for the HPV vaccine was appropriate” (Ferrer et al., 2014).
The cost of the vaccine not only affects the patient’s decision, but it also affects the
physician’s decision to buy and recommend the vaccine. The Vaccines for Children (VFC)
program has been developed to “remove cost as a barrier for the immunization of children.” This
program is federally funded and it offers free vaccines for Medicaid-eligible children, Native
American or Alaskan children, and uninsured or underinsured children. Vaccines are bought
from the manufacturers at a very low cost and distributed among physicians free-of-charge to
encourage them to vaccinate all their eligible patients (Malo et al., 2013).
In Denmark, the quadrivalent vaccine is offered free-of-charge to 12-year-old girls, and
to girls ages 13-15 under the catch-up immunization program. The Danish National Board of
Health has also taken the initiative to inform all eligible girls by mail to encourage maximum
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coverage of vaccination. This has ensured about 67-76% rates of vaccination among girls born
from 1993 to 1995 (Mortensen, 2010).
Provider Encouragement and Recommendations
It has been shown that the success of HPV vaccine in controlling the incidence of
cervical cancer in women largely depends upon the rate at which pediatricians recommend the
vaccine to parents of their eligible patients. Overall, physicians’ attitudes towards the vaccine
seem positive, and in a number of places they are found to actively recommend the vaccine to
their patients (Krieger, Katz, Kam, & Roberto, 2012).
There are three types of healthcare providers who routinely recommend the vaccine to
patients aged 9 – 26 years; pediatricians, family physicians, and obstetricians. Data obtained
from this survey showed that 34.6% of physicians recommended the vaccine to early
adolescents, 52.7% recommended to middle adolescents, and 50.2% recommended the vaccine
to late adolescents. Also, according to this study, “Pediatricians were significantly more likely
than family physicians and obstetricians to “always” recommend HPV vaccination for almost all
female age groups” (Vadaparampil et al, 2011).
It is well known that provider recommendation is a strong predictor of whether a parent
decides to vaccinate a child against HPV. Studies show that 55% of parents who have received a
physician’s recommendation vaccinate their sons against HPV, as compared to only 1% of
parents who had their son vaccinated but had not received a physician’s recommendation.
According to this study, “Physician recommendation and education about HPV vaccine for
males may be key strategies for improving vaccination” (Reiter et al., 2013). According to
another study, “Recommendation of HPV immunization by primary care physicians (PCPs) has
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been recognized as one of the most influential factors in the individual’s willingness to receive
the vaccine” (Wong et al., 2013).
Support from EHRs and Health Information Systems
The importance of health information systems in vaccination is the “timely availability of
sound data.” These systems are responsible for the generation, analysis, and dissemination of
such data to the concerned people for appropriate action. This data can also be used to influence
research, policy making, and program generation. It uses data-generation methods such as
household surveys, censuses, and administrative returns to identify the number of children who
have not been vaccinated. This data is then analyzed for research purposes, to find out the
prevalence of vaccination in a certain population and to identify trends and/or barriers. This
information can then be used to improve the uptake of vaccines (AbouZahr & Boerma, 2005).
In the US, technologies including text messaging, email, social media, and electronic
health records are used improve immunization rates. Improvements in the field of Health
Information Technology help in the identification of children who have not been vaccinated and
alert their parents of their child’s immunization schedule. According to current data, “The Health
Information Technology for Economic and Clinical Health (HITECH) Act, part of the American
Reinvestment and Recovery Act of 2009, included monetary incentives tied to meaningful use of
Electronic Health Records (EHRs)” (Stockwell & Fiks, 2013).
A number of interventions have been put in place to aid immunization uptake by the
target population. One of the interventions involves electronic health record-derived
immunization prompts that alert the physician when an unimmunized patient visits the clinic.
Another intervention involves sending quarterly reports to the physician regarding the
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immunization status of his/her patients, enabling the physician to send reminders to the
unimmunized patients (Bundy et al., 2013).
Support from Healthcare Information Security and Privacy
Using electronic means to document patient data requires the collection of extensive
personal and health-related patient information. This kind of data collection and storage can
compromise privacy and can be used against him/her in insurance, employment, and government
programs. For these reasons, the Model State Public Health Privacy Act provides guidelines to
protect public health data, at the same time allowing state and local public health departments to
use the data for the common good (Gostin, Hodge, & Valdiserri, 2001).
In particular, the American Recovery and Reinvestment Act (ARRA) of 2009
significantly focused on the issues of security and privacy of healthcare information. Before the
enactment of the ARRA, the topic of information privacy had been stressed by the U.S.
Government Accountability Office (GAO) and its efforts have led to stricter guidelines. This Act
has increased the control an individual has over his/her health information and the individual can
also restrict disclosure of this information. It also requires the signing of business associate
contracts if the health information of a person needs to be shared with business associates for
research purposes (Goldstein, 2010).
The fear of breach of privacy resides not only with the patients, but also with the
provider. Providers are often wary of revealing their patients’ data to third parties for fear of
misuse of the information. According to a study, “Providers under-report notifiable disease cases
to public health agencies.” These concerns have been taken care of by the Canadian jurisdiction
and the U.S. Health Insurance Portability and Accountability Act (HIPAA) Privacy rule (Emam
et al., 2011).
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Support from Regulatory Environment
Legislative action has worked positively towards increasing awareness about HPV
vaccination among parents and the general public. In a study, about 63.5% of the women said
that they were more inclined to follow a law that made HPV vaccination mandatory for children.
According to the study, “A majority expressed a high intent to comply with a hypothetical law
mandating adolescent HPV vaccination for school attendance” (Carlos et al., 2011).
In the US, the Centers for Disease Control and Prevention (CDC) and the World Health
Organization (WHO) have published safety reports on the HPV vaccine. The CDC has also
conducted post-licensing studies to assess the safety of the quadrivalent vaccine, Gardasil
(Fernandez et al., 2012). With the involvement of the Advisory Committee on Immunization
Practices (ACIP) of the CDC in recommending vaccination for girls ages 11-12 and catch-up
vaccination for girls ages 13-26, a number of bills have been passed making the HPV vaccine
mandatory for school children (Mello, Abiola, & Colgrove, 2012).
A national, non-profit organization called Women in Government (WIG) has been
involved in the legislation pertaining to HPV vaccination. Upon receiving educational grants
from Merck, WIG conducted a number of educational conferences attracting a number of
legislators involved in the work relating to HPV vaccination. According to one remark, “WIG bit
off hook, line, and sinker the need to have mandated this vaccination across America” (Mello et
al., 2012).
In Europe, the European Medicines Agency (EMA) has allowed for the use of the
quadrivalent vaccine in females up to 46 years old and in males up to age 26. This
recommendation is the “basis for vaccine approval for males and male vaccination
recommendations by EMA (Crosignani et al., 2013).
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Support from State Policies
State policies and other regulatory activities have been highly instrumental in improving
the uptake of the HPV vaccine. The efforts usually deal with financing HPV vaccination through
the Vaccines for Children (VFC) program, Medicaid and private insurance, laws relating to
mandatory HPV vaccination, and educational campaigns about HPV vaccination. According to a
study, “To increase coverage, many states have introduced legislation to require private
insurance companies to cover the HPV vaccine.” Some states have also supplemented federal
funds and started providing the vaccine at very little or no cost. Another policy to increase
uptake of the vaccine is to introduce mandates for school children and immigrants. Some states
have also made it compulsory that information about HPV vaccines should be included as part of
the curriculum of sex education in schools (Fernandez et al., 2010).
Policies with respect to vaccination usually focus on the target age group for the
particular vaccine, the age group that can be considered for a catch-up program, revisions of
screening policies with respect to HPV DNA testing, and inclusion of boys for HPV vaccination
programs (Kim, Brisson, Edmunds, & Goldie, 2008). “Cost-effectiveness evaluations are
designed to assist in population-level decision-making at a government or policy-maker
perspective” (Canfell et al., 2012).
Some states have also incorporated default policies to allow individuals to opt-in or optout of health services. Such policies have had a very positive effect on influenza vaccination and
organ donation in the past. According to a study, default policies were found to make the parents
more likely to get their children vaccinated against HPV (Reiter et al., 2012).
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Support from the U.S. National Vaccine Plan
The U.S. National Vaccine Plan was implemented with the aim of achieving five goals –
to develop new and better vaccines, to improve the safety profiles of the existing vaccines, to
improve decision-making to enhance vaccines, to provide access to all vaccines within the US,
and to help combat global diseases better through vaccination. The National Vaccine Plan
implemented in 2010 aimed to build a stronger health system by improving the uptake of
preventative vaccines. In following the guidelines of the National Vaccine Plan, a child can be
protected against 17 diseases through vaccination, and a number of financial barriers that earlier
restricted the uptake of vaccines, have now been removed (US Department of Health and Human
Services, 2010).
The priorities in the National Vaccine Plan implementation guidelines include developing
a list of all important vaccines, enabling easier development and licensing of new vaccines,
encouraging studies on vaccine safety, improving awareness of important vaccines among the
public, working on removing financial barriers for the physicians and the public, encouraging the
use of health information technology and electronic health records (EHRs), and encouraging the
global introduction of important vaccines to help eradicate diseases (US Department of Health
and Human Services, 2010).
As of 2014, leaders involved in decisions regarding implementation of the National
Vaccine Plan are looking for areas that need intervention in the current context. Some of the
priorities include improving communication with the providers, improving access to health
insurance and other measures taken to protect public health, improving the rates of adult
immunization, and in improving coverage of HPV vaccination among adolescents.
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Future Directions for Research
This literature review has thrown light upon the various barriers and the supports that
exist for healthcare professionals in recommending HPV vaccination. There are many classes of
hindrances and supports that exist for healthcare workers, parents, and young men in terms of
knowledge, safety and efficacy, financial matters, cultural issues, and psychological barriers.
Very little is known about the prevalence of physician recommendations and organizational
encouragements.
Future research in this field needs to focus on capturing better data concerning unhealthy
behaviors among people. Major challenges include small sample sizes, low response rates,
convenience samples, lack of appropriate evidence-based theories, and hypothetical story lines.
Hence, it is important to analyze the healthcare professionals’ current outlook on HPV
vaccination, the uptake of these vaccines by male adolescents, and the introduction of new state
policies concerning HPV vaccine for increasing knowledge in this domain. It is also important to
determine the actual behaviors of the healthcare professionals involved with respect to HPV
vaccination, especially for pre-adolescent and adolescent males.
Future research should also focus on the attitudes of the adolescents as well as their
parents concerning HPV vaccination. In order to decrease the prevalence of HPV, adolescents
will need motivation from parents or other role models to change their attitude towards
vaccination.
Conclusions on Literature Review
This literature review has summarized commonly identified barriers people might face in
getting themselves or their children vaccinated against HPV, and barriers that might prevent
primary healthcare providers from recommending the vaccine to their patients. As expected, the
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barriers vary with geographical location, ethnicity, gender, age group, financial status, societal
influences, religious beliefs, and family or peer pressure.
The governments of various countries have not been blind to these barriers, and a number
of steps have been taken to make it easier for healthcare providers and patients to decide to
acquire vaccination against HPV. For example, the National Vaccine Plan was developed in
1994 to spread awareness about the benefits of acquiring vaccines. With assistance from the
National Institute of Health (NIH), more than 20 new vaccines have gained approval from the
Food and Drug Administration (FDA). These include vaccines against pediatric pneumococcal
disease, meningococcal disease, and HPV (Teitelbaum & Wilensky, 2012).
Vaccines for Children (VFC) is a federally funded program that has been implemented to
provide essential vaccines for free to children (Katz et al., 2009). The CDC and the WHO Global
Advisory Committee on Vaccine Safety have taken a number of measures to assess the safety of
the HPV vaccines. The CDC has also conducted post-licensing studies to evaluate the safety of
the quadrivalent vaccine, Gardasil (Fernandez et al., 2010). Other organizations that work hard to
ensure maximum coverage of important vaccines include the Institute of Medicine (IOM), the
U.S. Advisory Committee on Immunization Practices, the Department of Health and Human
Services (HHS), the National Vaccine Program Office (NVPO), and the Health Resources and
Services Administration (Chesson, Bladford, Gift, Tao, & Irwin, 2008; Thaul, 2005).
Thus, although barriers are many, efforts to overcome them are constantly being initiated
and modified to ensure optimum health for all citizens. The US health departments in particular
have taken many initiatives such as publicly available insurance policies and school-based
immunization programs to provide the maximum protection against infectious diseases at the

56
least inconvenience to the public. It is highly plausible that the listed barriers against HPV
vaccination will soon be overcome in the ongoing effort to create healthy lives and environment.
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CHAPTER 3
RESEARCH METHODS
Nature of Research Study
The study design for this research is cross-sectional and observational, based on
secondary source of data.
Data
Clinical specialty data for HPV vaccine recommendation among adolescent males were
drawn from the 2014 profile of rural healthcare providers of all 10 affiliates of Albany Area
Primary Health Care, Inc.. Albany Area Primary Health Care, Inc. is an affiliate of the Georgia
Association for Primary Health Care (GAPHC) and also a Federally Qualified Health Center
(FQHC). It is located in Albany, GA, and provides healthcare services to rural and underserved
communities in southwest GA. Questions on perceived barriers and rates of HPV vaccination
recommendations were administered as a paper-based survey instrument to a representative
sample of 70 clinical specialists (family practice, pediatricians, and nurse practitioners) and
completed by 51 healthcare providers. The response rate for the healthcare providers was 76%.
Albany Area Primary Health Care adopted a previously validated survey tool developed
by researchers from the Moffitt Cancer Center and tested by Susan Vadaparampil (2009) from a
nationwide survey. The research study conducted by Susan Vadaparampil was on HPV
intervention. The researchers validated the instrument through two rounds of expert panel
review with HPV researchers and clinicians, as well as through interviews with physicians (n =
7) and a pilot study with randomly selected physicians (n = 16) with expertise in this field
(Vadaparampil et al., 2011).
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The purpose of this study was to examine the healthcare provider’s inclinations regarding
recommendation of HPV vaccine for male adolescents, especially those ages 11–12, 13–17, and
18–26. The secondary data was drawn from data provided to the researcher that was obtained
through a survey taken by a sample of medical practitioners based on their experiences in dealing
with the target sample of male patients between the ages of 11 and 26 years old. Based on the
responses obtained from this target sample of healthcare providers in the Albany Area Primary
Care, inferences will be made on the entire population of patients in these age groups. The
Institutional Review Board of Georgia Southern University approved exemption status for this
research.
Variables
The research study used variables such as age of male patients, clinical specialties of the
respondent health workers, frequency of recommendation for vaccine uptake, frequency of
vaccine administration, parent’s fears and concerns on the effects of the vaccine being
administered. Paired t tests and analysis of variance (ANOVA) were used to determine the
relationships between provider recommendations to patients and vaccine uptake completion. The
primary variables in this research study were the specialty of practice, age of target patients,
gender of the practitioners, and race. These variables were analyzed against each other with the
independent variable being age, gender, and specialty of medical practice. The main dependent
variables were the frequency with which health providers to recommend the HPV vaccine as
well as the frequency of administration of this vaccine to the target population of male patients in
the chosen age groups.
General Demographics of the Target Population
In accordance to Federal Regulations Title 45 Part 46, this research study was determined
not to require full review and was exempted by the Georgia Southern University Institutional
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Review Board (GSU-IRB). This was due to the fact that the study involved the use of publicly
available data as well as participants who cannot be identified. Upon subsequent approval by the
GSU-IRB, the publicly available secondary data (N = 51) was obtained from Albany Area
Primary Health Care (AAPC), Incorporated. AAPC is a FQHC, headquartered in Albany,
Georgia and has clinics in several surrounding rural counties in southwest Georgia providing
care to 35,000 diverse individuals and seeing 120,000 patient visits per annum. The facilities
deliver services to children and adults through primary healthcare providers such as family
physicians, pediatricians, and nurse practitioners. According AAPC, out of this population, data
was randomly collected pertaining to adolescents in the age groups of 11-12 years, 13-17 years,
and 17 – 26 years. A total representative sample of 15 family practitioners, 17 nurses, and 19
pediatricians were used in this study to collect data on the frequency of HPV vaccine
recommendation to their patients in the varying age categories.
Statistical Analysis
Paired t tests and ANOVA were carried out in investigating the statistical differences that
exist between the clinical specialties. The research revolves around the recommendation of the
HPV vaccine among the various age groups, which in effect means that the primary response in
this analysis was health provider recommendations of HPV vaccination. The dependent variables
obtained in this research study were based on the Likert-type scale, offered in the questionnaires
administered to the various health providers. An assumption was made that responses by the
health sector service providers in the sample were representative of the general approach by each
of the medical practitioners in dealing with all his/her clients in as far as recommending the HPV
vaccine. This recoding was selected as most appropriate as it reflects best practices employed by
health providers in recommending the vaccine.
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CHAPTER 4
RESULTS
This section presents the results of our analyses in responses to the questions listed in
Chapter 1. All analyses were performed in SPSS, version 23. This study explored providers’
tendency to recommend HPV vaccine to early male adolescents (age 11–12); as evidence
indicates that this is the most preferred age to introduce the HPV vaccine to ensure long-term
effectiveness. The frequencies and percentages for the healthcare providers’ demographic
characteristics can be found in Table 1. There were 54 healthcare providers that data was
gathered from in the study. The majority were nurses (N = 33, 64.7%) followed by family
medicine workers (N = 12, 23.5%) and the smallest group was pediatrics (N = 6, 11.8%). Three
of the providers did not indicate their field of specialty.
Provider age varied. The majority were 24-32 years of age (N = 22, 41.5%). Next in
respective order were 42-50 years of age (N = 14, 26.4%), 33-41 years of age (N = 12, 22.6%)
and 51 years of age or older (N = 5, 9.4%). One provider did not indicate their age.
Gender representation was not balanced among providers. The majority were female (N
= 44, 84.6%) and the rest male (N = 8, 15.4%). Two providers did not indicate their gender.
Race was varied among providers with white being the majority (N = 29, 55.8%) of this sample.
Respectively followed by black (N = 18, 34.6%), prefer not to answer (N = 2, 3.8%), Asian (N =
1, 1.9%), native Hawaiian/pacific islander (N = 1, 1.9%), and mixed race (N = 1, 1.9%). Two
providers did not identify and racial category.
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Table 1
Frequencies and Percentages for Healthcare Providers’ Background Characteristics
Provider Characteristic

Frequency

Percent

Pediatrics

6

11.8

Family Medicine

12

23.5

Nurses

33

64.7

Total

51

100.0

24 - 32 years

22

41.5

33 - 41 years

12

22.6

42 - 50 years

14

26.4

51+

5

9.4

Total

53

100.0

Male

8

15.4

Female

44

84.6

Total

52

100.0

White / Caucasian

29

55.8

Asian

1

1.9

Native Hawaiian / Pacific Islander

1

1.9

Black / Black American

18

34.6

Mixed race

1

1.9

Prefer not to answer

2

3.8

Total

52

100.0

Type of Healthcare Provider

Provider Age

Provider Gender

Provider Race
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Research Question A
Research Question A was, are healthcare providers' rates of recommending HPV
vaccination for males aged 11 to 12 years old higher than those of males aged 13 to 17 years old?
Null Hypothesis: No difference exists between healthcare providers’ prevalence of
recommending HPV vaccines to either early (ages 11-12) adolescent or middle (ages 1317) adolescent males.
Alternate Hypothesis: A difference exists between the healthcare providers’ prevalence of
recommending HPV vaccines to early (ages 11-12) adolescent and middle (ages 13-17)
adolescent males.
A paired samples t test was used to address the hypotheses. The null hypothesis was retained
(t(46) =-1.771, p = .083). There was no significant difference found between healthcare
providers’ prevalence of recommending HPV vaccines to either early (ages 11-12) adolescents
(M = 2.51, SD = 1.988) or middle (ages 13-17) adolescent males (M = 2.64, SD = 1.983). See
Table 2.
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Table 2
Paired Samples T Test for Recommending HPV Vaccines to Either Early (Ages 11-12)
Adolescent or Middle (Aged 13-17) Adolescent Males
Paired Differences
Mean

Std.
Deviation

SE
Mean

95% Confidence
Interval of the
Difference
Lower Upper

t

df

Sig.

-1.771

46

.083

recommend
vaccine to 11-.128

.494

.072

-.273

.017

12yrs versus
13-17yrs

Research Question B
Research Question B was, are healthcare providers' rates of recommending HPV
vaccination for middle adolescent males (ages 13-17) higher than those of late adolescent (ages
18-26 years) males?
Null Hypothesis: No difference exists between healthcare providers’ prevalence of
recommending HPV vaccines to either middle adolescent or late adolescent males.
Alternate Hypothesis: Differences exist between healthcare providers’ prevalence of
recommending HPV vaccines to middle adolescent and late adolescent males.
A paired samples t test was used to address the hypotheses. The null hypothesis was retained
(t(46) =1.499, p = .141). There was no significant difference found exists between healthcare
providers’ prevalence of recommending HPV vaccines to either middle adolescents (M = 2.64,
SD = 1.983) or late adolescent males adolescents (M = 2.45, SD = 1.851). See Table 3.
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Table 3
Paired Samples T Test for Recommending HPV Vaccines to Either Middle Adolescent or Late
Adolescent Males
Paired Differences

Mean

Std.
Deviation

SE
Mean

95%
Confidence
Interval of the
Difference
Lower Upper

.191

.876

.128

-.066

t

df

Sig.

1.499

46

.141

recommend
vaccine to 13.449

17yrs versus
18-26yrs

Research Question C
Research Question C was, are healthcare providers' rates of recommending HPV
vaccination for late adolescent males (aged 11-12) higher than those of early adolescent males
(aged 18-26)?
Null Hypothesis: No difference exists between healthcare providers’ prevalence of
recommending HPV vaccines to either late adolescent (aged 11 -12) or early male
adolescent males (aged 18-26).
Alternate Hypothesis: Differences exist between healthcare providers’ prevalence of
recommending HPV vaccines to late adolescence (aged 11-12) and early adolescence
males (aged 18-26).
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A paired samples t test was used to address the hypotheses. The null hypothesis was retained
(t(46) =.443, p = .660). There was no significant difference found between healthcare providers’
prevalence of recommending HPV vaccines to adolescent (M = 2.45, SD = 1.851) late
adolescence (aged 13-17) and adolescent (M = 2.64, SD = 1.983) early adolescence males (aged
18-26). See Table 4.
Table 4
Paired Samples Test for Healthcare Providers’ Prevalence of Recommending HPV Vaccines to
Late Adolescence (Ages 11-12) and Early Adolescence Males (Ages 18-26)
Paired Differences

Mean

Std.
Deviation

SE
Mean

.064

.987

.144

95%
Confidence
Interval of the
Difference
Lower Upper

t

df

Sig.

.443

46

.660

recommend
vaccine to 11-.226

.354

12yrs - versus
18-26yrs

Research Question D
Research Question D was, is there a variation in rates at which specialist healthcare
providers’ (FPs, NPs, Peds) recommend HPV vaccines?
Null Hypothesis: No difference exists between specialist healthcare providers in their
prevalence of recommending HPV vaccines to patients.
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Alternate Hypothesis: Differences exist between specialist healthcare providers in their
prevalence of recommending HPV vaccines to patients.
ANOVA was used to address the hypotheses. The null hypothesis was retained for patients 11-12
years old (F(2,44) = 1.456, p = .244), as there were no difference in pediatric, family medicine,
and nurse healthcare providers’ prevalence of recommending HPV vaccines to patients in this
age group. The null hypothesis was retained for patients 13-17 years old (F(2,43) = 2.328, p =
.110) as there were no difference in pediatric, family medicine, and nurse healthcare providers’
prevalence of recommending HPV vaccines to patients in this age group. Finally, null hypothesis
was retained for patients 18-26 years old (F(2,43) = 1.511, p = .232) as there were no difference
in pediatric, family medicine, and nurse healthcare providers’ prevalence of recommending HPV
vaccines to patients in this age group. There are no difference exists between specialist
healthcare providers in their prevalence of recommending HPV vaccines to patients (see Table 5
and 6).
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Table 5
Group Means for Healthcare Provider Recommendation Rates
Type of Healthcare Provider

Pediatrics

Family medicine

Nurses

Total

recommend

recommend

recommend

vaccine to 11-

vaccine to 13-

vaccine to 18-

12yrs

17yrs

26yrs

M

1.50

1.67

1.50

N

6

6

6

SD

0.837

0.816

0.837

M

3.08

3.50

3.00

N

12

12

12

SD

1.730

1.567

1.537

M

2.34

2.36

2.29

N

29

28

28

SD

2.092

2.129

1.979

M

2.43

2.57

2.37

N

47

46

46

SD

1.920

1.940

1.793
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Table 6
ANOVAs for Specialist Healthcare Providers in Their Prevalence of Recommending HPV
Vaccines to Patients
Age Group

Sum of

df

Squares
recommend vaccine

Between

to 11-12yrs

Groups

Mean

2

5.260

Within Groups

158.968

44

3.613

Total

169.489

46

recommend vaccine

Between

16.542

2

8.271

to 13-17yrs

Groups
Within Groups

152.762

43

3.553

Total

169.304

45

9.503

2

4.752

Within Groups

135.214

43

3.145

Total

144.717

45

Between

to 18-26yrs

Groups

Sig.

1.456

.244

2.328

.110

1.511

.232

Square

10.521

recommend vaccine

F

Research Question E
Research Question E was, are healthcare providers' encountering perceived barriers in
recommending HPV vaccine to adolescent males?
Null Hypothesis: No perceived barriers exist among healthcare providers’ prevalence of
recommending HPV vaccines to adolescents males.
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Alternate Hypothesis: Perceived barriers exist among healthcare providers’ prevalence of
recommending HPV vaccines to adolescents males.
Frequencies and percentages were used to address the hypotheses. The null hypothesis is rejected
because perceived barriers were reported among healthcare providers’ prevalence of
recommending HPV vaccines to adolescents males in discussing sexuality, vaccinating teens
with riskier sexual behavior, adding another vaccine to the vaccine schedule, and when
vaccination is not required for school attendance (see Table 7).
Providers were asked five questions about perceived barriers were reported among
healthcare providers’ prevalence of recommending HPV vaccines to adolescents males. In the
first question, discussing sexuality, the majority answered (N = 17, 32.1%), followed by strongly
agree (N = 16, 30.2%), strongly disagree (N = 11, 20.8%), somewhat disagree (N = 11, 20.8%),
and neutral (N = 3, 5.7%). The second question was about vaccinating teens with riskier sexual
behavior. The majority answered strongly agree (N = 21, 40.4%), somewhat agree (N = 13,
25.0%), somewhat disagree (N = 9, 17.3%), strongly disagree (N = 5, 9.6%), and neutral (N = 4,
7.7%). The third question was adding another vaccine to vaccine schedule. The majority
answered somewhat disagree (N = 15, 28.3%) followed by neutral (N = 13, 24.5%), somewhat
agree (N = 13, 24.5%), strongly disagree (N = 8, 15.1%), and strongly agree (N = 4, 7.5%). The
fourth question asked do you take time to discuss HPV with patients/parents. The majority
answered both somewhat disagree (N = 14, 26.4%) and somewhat agree (N = 14, 26.4%)
followed by neutral (N = 12, 22.6%), strongly disagree (N = 7, 13.2%), and strongly agree (N =
6, 11.3%). The final question asked should vaccination not required for school attendance. The
majority answered somewhat agree (N = 14, 26.4%), followed by somewhat disagree (N = 12,
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22.6%), neutral (N = 12, 22.6%), strongly disagree (N = 10, 18.9%), and strongly agree (N = 5,
9.4%).
Table 7
Frequency and Percentages for Healthcare Providers' Encountering Perceived Barriers in
Recommending HPV Vaccine to Adolescent Males
Barriers

Frequency

Percent

Strongly disagree

11

20.8

Somewhat disagree

6

11.3

Neutral

3

5.7

Somewhat agree

17

32.1

Strongly agree

16

30.2

Total

53

100.0

Strongly disagree

5

9.6

Somewhat disagree

9

17.3

Neutral

4

7.7

Somewhat agree

13

25.0

Strongly agree

21

40.4

Total

52

100.0

Strongly disagree

8

15.1

Somewhat disagree

15

28.3

Neutral

13

24.5

Somewhat agree

13

24.5

Strongly agree

4

7.5

Total

53

100.0

7

13.2

Discussing Sexuality

Riskier Sexual Behavior

Adding Another Vaccine to Vaccine Schedule

Takes Time to Discuss HPV with Patients/Parents
Strongly disagree
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Somewhat disagree

14

26.4

Neutral

12

22.6

Somewhat agree

14

26.4

Strongly agree

6

11.3

Total

53

100.0

Strongly disagree

10

18.9

Somewhat disagree

12

22.6

Neutral

12

22.6

Somewhat agree

14

26.4

Strongly agree

5

9.4

Total

53

100.0

Vaccination is not Required for School Attendance

Research Question F
Research Question F was, is there variation in recommending rates by demographic
characteristics of the provider?
Null Hypothesis: There is no variation in recommending rates by demographic
characteristics of the provider.
Alternate Hypothesis: There is variation in recommending rates by demographic
characteristics of the provider.
ANOVAs were used to address the hypothesis.
Provider age. The first set of ANOVAs were used to examine average differences in
referral rates by provider age. The null hypothesis was retained for patients 11-12 years old
(F(3,43) = 2.319, p = .088), 13-17 years old (F(3,43) = 2.252, p = .096), and 18-26 years old
(F(3,43) = 2.195, p = .102) when the independent variable was provider age (see Tables 8 & 9).
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Table 8
Recommendation Rates by Age of Provider and Age of Vaccination Recipient
Provider age

24 - 32 years

33 - 41 years

42 - 50 years

51+

Total

recommend

recommend

recommend

vaccine to 11-

vaccine to 13-

vaccine to 18-

12yrs

17yrs

26yrs

M

2.21

2.42

2.32

N

19

19

19

SD

1.843

1.895

1.797

M

3.58

3.67

3.42

N

12

12

12

SD

2.021

1.969

2.065

M

2.38

2.50

2.17

N

13

12

12

SD

2.063

2.111

1.697

M

1.00

1.00

1.00

N

4

4

4

SD

.000

.000

.000

M

2.50

2.64

2.45

N

48

47

47

SD

1.968

1.983

1.851
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Table 9
ANOVAs for Age of Provider and Age of Vaccination Recipient
Sum of

df

Squares
recommend

Between

vaccine to 11-12yrs

Groups

Mean

Sig.

2.319

.088

2.252

.096

2.195

.102

Square

24.849

3

8.283

157.151

44

3.572

Total

182.000

47

recommend

Between

24.553

3

8.184

vaccine to 13-17yrs

Groups
156.298

43

3.635

Total

180.851

46

recommend

Between

20.928

3

6.976

vaccine to 18-26yrs

Groups
136.689

43

3.179

157.617

46

Within

F

Groups

Within
Groups

Within
Groups
Total

74

Provider race. The next set of ANOVAs were used to examine average differences in
referral rates by provider race. The null hypothesis was retained for patients 11-12 years old
(F(5,41) = 1.398, p = .245), 13-17 years old (F(5,40) = 1.345, p = .226), and 18-26 years old
(F(5,40) = 1.586, p = .186) when the independent variable was provider race (see Tables 10 &
11).
Table 10
Recommendation Rates by Provider Race and Age of Vaccination Recipient
Provider race/ethnicity

White / Caucasian

Asian

Native Hawaiian / Pacific Islander

Black / Black American

Mixed race

recommend

recommend

recommend

vaccine to

vaccine to 13-

vaccine to

11-12yrs

17yrs

18-26yrs

M

2.24

2.32

2.16

N

25

25

25

SD

1.964

1.952

1.930

M

5.00

5.00

5.00

N

1

1

1

SD

.

.

.

M

1.00

1.00

4.00

N

1

1

1

SD

.

.

.

M

2.82

2.88

2.41

N

17

17

17

SD

1.944

1.965

1.583

M

6.00

6.00

6.00

N

1

1

1
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Prefer not to answer

Total

SD

.

.

.

M

1.50

1.00

1.00

N

2

1

1

SD

.707

.

.

M

2.53

2.61

2.41

N

47

46

46

SD

1.977

1.994

1.857

Table 11
ANOVAs for Race of Provider and Age of Vaccination Recipient
Sum of

df

Squares
recommend vaccine to 11-

Between

12yrs

Groups

Mean

F

Sig.

1.398

.245

1.345

.266

1.586

.186

Square

26.172

5

5.234

Within Groups

153.531

41

3.745

Total

179.702

46

recommend vaccine to 13-

Between

25.752

5

5.150

17yrs

Groups
Within Groups

153.205

40

3.830

Total

178.957

45

recommend vaccine to 18-

Between

25.675

5

5.135

26yrs

Groups
Within Groups

129.478

40

3.237

Total

155.152

45
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Provider gender. The next set of ANOVAs were used to examine differences in referral
rates by provider gender. The null hypothesis was retained for patients 11-12 years old (F(1,45)
= 0.022, p = .883), 13-17 years old (F(1,44) = 0.218, p = .643), and 18-26 years old (F(1,44) =
0.020, p = .887) when the independent variable was provider gender (see Tables 12 & 13).
Table 12
Referral Rates by Gender of Provider and Age of Vaccination Recipient
Provide gender

Male

Female

Total

recommend

recommend

recommend

vaccine to 11-

vaccine to 13-

vaccine to 18-

12yrs

17yrs

26yrs

M

2.43

3.00

2.57

N

7

7

7

SD

1.618

1.633

1.397

M

2.55

2.62

2.46

N

40

39

39

SD

2.050

2.060

1.945

M

2.53

2.67

2.48

N

47

46

46

SD

1.977

1.989

1.859

77
Table 13
ANOVAs for Gender of Provider and Age of Vaccination Recipient
Sum of

df

Squares
recommend vaccine to

Between

11-12yrs

Groups

Mean

1

0.088

Within Groups

179.614

45

3.991

Total

179.702

46

.878

1

0.878

Within Groups

177.231

44

4.028

Total

178.109

45

.072

1

0.072

Within Groups

155.407

44

3.532

Total

155.478

45

Between

13-17yrs

Groups

recommend vaccine to

Between

18-26yrs

Groups

Sig.

0.022

.883

0.218

.643

0.020

.887

Square

.088

recommend vaccine to

F
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Summary
Data were gathered from 54 healthcare providers. The majority were nurses followed by
family medicine workers, and providers in pediatrics. Provider age varied, but was on the young
side since these were students. The majority of providers were also White and female.
The null hypothesis was retained on four of five research questions. For the Research
Question A, there were no statistically significant differences between healthcare providers’
prevalence of recommending HPV vaccines to either early (ages 11-12) adolescent or middle
(ages 13-17) adolescent males. For Research Question B, there were no statistically significant
differences between healthcare providers’ prevalence of recommending HPV vaccines to either
middle adolescent or late adolescent males. For Research Question C, there were no statistically
significant differences between healthcare providers’ prevalence of recommending HPV
vaccines to either late adolescent (ages 11 -12) or early male adolescent males (ages 18-26).
For Research Question D, there were no statistically significant differences in rates at
which specialist healthcare providers recommended HPV vaccines. The null hypothesis was
rejected for Research Question E. Perceived barriers were reported among healthcare providers’
prevalence of recommending HPV vaccines to adolescents males in discussing sexuality,
vaccinating teens with riskier sexual behavior, adding another vaccine to vaccine schedule, and
when vaccination is not required for school attendance. For Research Question F, there were no
statistically significant differences in recommending rates by demographic characteristics of the
provider.
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CHAPTER 5
SUMMARY DISCUSSION AND CONCLUSIONS
Discussion
While the CDC clearly recommends the HPV vaccine for boys and girls ages 11-12, the
results here and in the literature review show a marked preference by FPs, NPs, Peds, and
parents to vaccinate at a later age. There is some uneasiness among healthcare providers and
parents regarding the vaccination of pre-teens when it concerns a sexually transmitted disease.
Perhaps by educating healthcare providers on how to address these concerns with parents, the
rate of HPV vaccination among the younger population will improve. It is also important to
increase the awareness of healthcare providers and parents to the role that males play in the
spread of HPV so that more of them are vaccinated. While it is true that HPV vaccines at first
were only recommended for females, the CDC’s current recommendation is that all children
should be vaccinated by 11 or 12.
The HPV vaccine is currently not required by many state governments, including that of
Georgia. This determination is made by the states themselves and some considerations that are
taken into account are support by the community, monetary requirements for implementation,
burden on school personnel for enforcement, and supply of the vaccine (CDC, 2014). The CDC
(2014) also reported that because the HPV vaccine was first recommended for girls only, many
states did not want to put into action a requirement that would only apply to half of their student
population. However, since the CDC now currently recommends that all children, male and
female, receive a three-dose series of the vaccination starting at 11 or 12 years old, it may be
time for the states to revisit their policies of not making HPV vaccination a requirement.
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Also, in regards to the three-dose series, many patients and families may not be able to
complete all three doses due to financial or logistical reasons. While receiving one or two doses
is better than not being vaccinated at all, healthcare providers need to stress the importance of
completing the series and should find ways of not making the three-dose sequence a barrier to
completion.
HPV-related infections are common in the United States and, it is estimated that up to 79
million people are already infected. It is also estimated that 14 million new infections will occur
each year in people ages 15–59. Half of these new infections occur among people ages 15–24,
making this a high-risk group. Based on this assertion, it becomes crucial to understand the
questions that must be answered in scaling down this enormous infection rate in this group. Since
the minimum indicated age in this risk group is 15 years, it is imperative to ascertain the
mitigating factors that need to be adopted to avert this scenario.
The HPV vaccine is usually administered in up to three doses over a period of six months
to protect against HPV infections. The main HPV vaccines are Cervarix and Gardasil. The
Gardasil type protects against anal cancer and genital warts, and is highly recommended for
males, but can also be administered to females. These vaccines provide protection for patients
who receive all three doses of the vaccine and have adequate time to develop immunity, well
before they engage in sexual activities that will expose them to infections. For this reason, the
HPV vaccine should be administered to patients in the range of 11 to 12 years of age to mitigate
the sexual risk factors associated with the teenage life and later adolescence. For various reasons
that may lead to some boys not getting vaccinated during this age bracket, the vaccination is
open to other age groups ranging from 13 to 26, although for male patients the HPV vaccination
is recommended only up to the age of 21. However, for males who engage in sexual behavior
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with other males, or who have weak immune systems (such those suffering from HIV and other
ailments that weaken the immune system) the vaccine should be administered up to the age of
26, especially if the required doses have not been administered earlier. Due to the higher risks
posed to females by HPV-related infections including cervix cancer, the vaccine is generally
preferred for females. But as discussed earlier, the risks for males are equally troublesome. For
this reason the research delved into the factors that affect the recommendation and administration
of this vaccine specifically for those male patients who had sought the health services of FPs,
PEDs, and NPs. The health practitioners were assumed to be the main avenue through which
recommendation of the vaccine and its consequent administration would occur. In addition to
this, it is assumed that by consenting to administration of the HPV vaccine, all the requisite doses
were completed in the required intervals and no non-conformity was evidenced. The research
divided the age groups in this form to cover the preferred vaccination age of 11 to 12 years, the
high-risk ages of 13 to 17, and the ages of up to 26 years to cover those male patients who may
have been left out, as well as those with compromised immune systems. Other assumptions made
were on the availability of the HPV vaccine where this research assumed that the vaccine is
always available for administration. Furthermore it is assumed that the health providers
recommended the vaccine uniformly and sufficiently to all male patients and not just to some. It
was also not apparent to this researcher if the health practitioners detailed the individual benefits
of getting an HPV vaccination to the male patients, especially in regards to anal cancer and
genital warts. Details to this effect would have served to change the perception held by the male
patients in accepting the vaccine and having it administered to them. The ACIP has placed its
recommendation on administering the vaccine to all girls between the ages of 11 and 12, before
they become sexually active. It’s been imperative to enlist boys in this schedule to accommodate
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the health risks that face them, too. In late 2011, ACIP recommended routine vaccination of
males’ ages 11 to 12 using the quadrivalent human papillomavirus vaccine (HPV4, Gardasil).
The state of Georgia has engaged in a public awareness campaign aimed at creating
awareness of the existence of a vaccine that averts the occurrence of cancer. The campaign is
designed by the Georgia Department of Public Health (DPH), and the CDS-funded MARTA
organization has come up with awareness campaigns on HPV as a leading cause of cervical
cancer. The campaign urges parents to talk to their doctors about vaccinating their sons and
daughters. This policy change in approaching HPV vaccination marks a paradigm shift in the
manner in which vaccines are administered to the public, though much more is desired such as
making compulsory vaccinations a pre-requisite to admission to institutions of learning or access
to vocational centers. This approach would ensure a near-100% compliance with this
vaccination, although its introduction may face resistance from advocates of civil rights and
freedoms. The more subtle approach taken by the Georgia authorities is more of an appeal than a
requirement, and this may prompt the population to consider this vaccination as a mere option in
life. This is a fact that was evidenced in the report titled “Our Collaborative Course of
Action: Georgia’s Comprehensive Cancer Control Plan: 2013-2018.” This report was prepared
jointly by DPH and the Georgia Cancer Control Consortium (GC3), and it called for a change in
policy to create provisions for compulsory HPV vaccination.
Conclusion
The national guidelines that prescribe the recommended mode of HPV vaccine
administration have a focus on having persons between the ages of 11 and 26 vaccinated against
HPV. However, despite this policy requirement, health provider recommendations for this
vaccine are low, with an average of 16.2% saying that they recommend the vaccine to their
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patients in these age groups. This factor, accompanied by the low scores recorded in the
administration of this vaccine and parental barriers, leads to the conclusion that there exists an
array of missed clinical opportunities for HPV vaccination for the age groups in this survey. It is
therefore crucial that measures be taken to address all the noted barriers to effective vaccination,
and instruction provided to the health providers on the need to enhance recommendation of the
HPV vaccine to their patients. The results indicate that the measures must target the health
providers with respect to their specialty, age, and ethnic background. Emphasis should be made
on encouraging the health providers to recommend the vaccine without waiting for
recommendations the state authorities or the CDC.
Limitations
This research was conducted using secondary data obtained from Albany Area Primary
Health Care System located in southwest Georgia that provides healthcare services in 15
counties in the region. Data from the U.S. Census Bureau indicate that most of these counties are
small, rural locations with significant minority populations. Thus, the findings of this research
may not represent the entire population of regional primary healthcare providers accurately. The
sample size is small and the responses may be based on regional socio-cultural and socioeconomic factors, along with other regional factors. For example, religious and cultural beliefs
that are prevalent in southwest Georgia may have influenced reporting to the survey questions. In
this regard, there is a need for a similar, large-scale study using a larger sample size in order to
ascertain whether the findings of this research can be generalized to the entire population.
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